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Aspartate transcarbamoylase (ATCase) catalyzes the synthesis of N-carbamoyl-L-aspartate 
from carbamoyl phosphate and aspartate in the second step of the de novo biosynthesis of 
pyrimidines. In prokaryotes and plants, the first three activities of the pathway, namely 
carbamoyl phosphate synthetase (CPSase), ATCase and dihydroorotase (DHOase), are 
encoded as distinct proteins that function independently or in non-covalent association. In 
turn, in animals, CPSase, ATCase and DHOase are part of a 243 kDa multifunctional 
polypeptide named CAD whose up-regulation is essential for normal and tumor cell 
proliferation. Although the structures of numerous prokaryotic ATCases have been 
determined, there is no structural information about any eukaryotic ATCase. In fact, the only 
detailed structural information about CAD is that it self-assembles through its ATCase 
domain forming hexameric particles of 1.5 MDa. In this study, we report the cloning, 
expression and purification of the ATCase domain of human CAD. The recombinant protein, 
expressed in bacteria and purified with good yields, forms homotrimers in solution. 
Crystallization experiments, both in the absence and presence of the inhibitor PALA, yielded 
small crystals that diffracted X-rays to 2.1 Å resolution using synchrotron radiation. We have 
determined the structure of the human ATCase domain, the first example of a eukaryotic 
ATCase, confirming the overall similarity with bacterial homologues. Surprisingly, the 
enzymatic and biochemical characterization of human ATCase showed that this domain 
exhibits cooperativity effects that reduce the affinity for the anti-tumoral drug PALA. These 
results were unexpected since the prokaryotic ATCase catalytic trimers lack cooperativity 
between active sites. Combining structural, mutagenic and biochemical analysis we identified 
key structural elements in human ATCase for the necessary regulation and transmission of 
conformational changes leading to cooperativity between subunits. Mutation of one of these 
elements, the active site residue R2024, was recently found to cause the first non-lethal 
CAD-deficit. We reproduced this mutation in the recombinant human ATCase domain and 
measured its effect. Our data suggest that this arginine is part of a molecular switch that 
regulates the conformational equilibrium between low and high affinity states of the subunits 
for the ligands. To further understand the role of ATCase trimers in the assembly of CAD 
particles, we produced a bifunctional construct harbouring the DHOase and ATCase 
domains of human CAD together with the 91 amino acid interlinking sequence. We 
demonstrated that this construct assembles into hexamers in solution and that site-specific 
mutations preventing either the dimerization of DHOase or the trimerization of ATCase, 
results in DHOase-ATCase trimers and dimers respectively. These results indicate that the 
ATCase and DHOase domains form the structural core of CAD particles.  
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La aspartato transcarbamilasa (ATCasa) cataliza la síntesis de N-carbamil-L-aspartato a 
partir de carbamil fosfato y aspartato en el segundo paso de la síntesis de novo de 
pirimidinas. En procariotas y en plantas, las primeras tres actividades de esta ruta, llamadas 
carbamil fosfato sintetasa (CPSasa), ATCasa y dihidroorotasa (DHOasa), están codificadas 
como proteínas que funcionan de forma independiente o asociadas de forma no covalente. 
En cambio en animales CPSasa, ATCasa y DHOasa son parte de un polipéptido 
multifuncional de 243 kDa llamado CAD, cuya activación es esencial para la proliferación de 
células normales y tumorales. Aunque se conoce la estructura de numerosas ATCasas 
procariotas, la única información estructural detallada sobre CAD es que se auto-ensambla a 
través de su dominio ATCasa formando partículas hexaméricas de 1.5 MDa. En este estudio 
describimos la clonación, expresión y purificación del dominio ATCasa de CAD humana. La 
proteína recombinante, expresada en bacterias y purificada con buen rendimiento, forma 
homo-trímeros en solución. Los experimentos de cristalización, tanto en ausencia como en 
presencia del inhibidor PALA, produjeron cristales que difractan los rayos X a una resolución 
de 2.1 Å usando radiación de sincrotrón. Hemos determinado la estructura del dominio 
ATCasa humano, siendo la primera estructura de una ATCasa eucariota, confirmando la 
similitud general con los homólogos bacterianos. Sorprendentemente, la caracterización 
enzimática y bioquímica de la ATCasa humana mostró que este dominio exhibe propiedades 
cooperativas que reducen la afinidad por el compuesto anti-tumoral PALA. Combinando el 
análisis estructural, mutagénico y bioquímico hemos identificado elementos estructurales 
claves para la transmisión de cambios conformacionales que permiten la cooperatividad 
entre subunidades. La mutación de uno de estos elementos, el residuo del centro activo 
R2024, se ha descrito recientemente como la causa del primer déficit no letal de CAD. 
Hemos reproducido esta mutación en la ATCasa humana recombinante y medido su efecto. 
Nuestros datos sugieren que esta arginina es parte de un interruptor molecular que regula el 
equilibrio conformacional entre estados de baja y alta afinidad de las subunidades por los 
ligandos. Para comprender mejor el papel de los trímeros de ATCasa en la arquitectura de 
CAD, produjimos una construcción bifuncional que contiene los dominios DHOasa y ATCasa 
humanos. Hemos demostrado que esta construcción forma hexámeros en solución y que 
mutaciones específicas que previenen la dimerización de los dominios DHOasa o la 
trimerización de la ATCasa resultan respectivamente en la formación de trímeros o dímeros 
de DHOasa-ATCasa. Estos resultados prueban que los dominios ATCasa y DHOasa forman 
el esqueleto central de las partículas de CAD. 
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1. De novo synthesis of pyrimidine nucleotides 
 Purine and pyrimidine nucleotides are the activated precursors of nucleic acids. As 
such, they constitute the building blocks for the replication and storage of information in the 
DNA and for the transcription of the genetic information into messenger RNA. A large fraction 
of the nucleotide pool is also present in the form of ribosomes (ribosomal RNA), which 
accumulate more than 80 % of the total nucleic acids of rapidly growing mammalian cells 
(Bremer and Dennis, 1996, Lodish et al., 2000, Lane and Fan, 2015). Purine nucleotides 
carry out a number of other important functions, such as acting as the cellular currency of 
energy and as donors of phosphoryl groups by protein kinases (ATP and GTP), as enzymatic 
cofactors, or as second messengers (cyclic AMP and GMP) in signal-transduction pathways 
(Cooper, 2000). On the other hand, pyrimidines nucleotides play a central role in the 
activation of sugars (UDP-sugars) for the formation of glycogen and for protein glycosylation 
(Bülter and Elling, 1999). Pyrimidines also form an important nucleotide-lipid conjugate, 
CDP-diacilglycerol, a branch point precursors of phospholipids with great importance for the 
assembly of the plasmatic membrane in eukaryotes. Finally, uridine nucleotides are also 
described to act as extracellular messengers regulating a variety of physiological processes 
(Connolly and Duley, 1999) (Figure 1). 
 
 
Figure 1. Pyrimidine nucleotides. Schematic representation of the most common variants of 
pyrimidine nucleotides. 
 
 Cells can obtain nucleotides through two different metabolic pathways. On the one 
hand, purine and pyrimidine bases, either released during the turnover of nucleic acids and 
nucleotides or obtained from the diet, can be salvaged and recycled by the cell. In these 
salvage pathways, the nucleotide bases (e.g. uracil) are reconnected to a ribose sugar 
activated in the form of 5-phosphoribosyl-1-pyrophosphate (PRPP) by specific 
phosphoribosyl transferases (PRTs). In addition, nucleosides (e.g. uridine) can be 
phosphorylated by specific kinases into the phosphorylated form. On the other hand, 
nucleotides can be synthesized de novo (from scratch) using simple compounds. Whereas 
 34 
purine bases are made piece by piece directly onto a ribose structure, in de novo synthesis 
of pyrimidines the nitrogenous base is pre-assembled from bicarbonate, aspartate and 
glutamine, and later, attached to the activated 5-ribose unit, PRPP (Berg et al., 2002). 
 In this study, we focused our attention in de novo pathway for pyrimidine synthesis 
(Figure 2). This enzymatic route starts with the production of carbamoyl phosphate (CP) from 
bicarbonate, ammonia and two molecules of ATP, a reaction catalyzed by the carbamoyl 
phosphate synthetase (CPSase). In animals, there are two types of CPSases physically 
separated in different cell compartments. One CPSase, named type I, localizes in the 
mitochondria of hepatocytes and detoxifies ammonia by making CP in the urea cycle (Figure 
2) (Nyunoya et al., 1985, Tramell and Campbell, 1970). The second CPSase (type II) is 
cytosolic, and catalyzes the dedicated production of CP for the synthesis of pyrimidines 
(Simmer et al., 1990). This enzyme synthesizes CP in four partial reactions (Anderson and 
Meister, 1966). First, bicarbonate is phosphorylated to carboxyphosphate, which reacts with 
ammonia producing carbamate and inorganic phosphate. Then, carbamate is 
phosphorylated to yield CP. CPSase primarily uses glutamine as the source of ammonia. 
The hydrolysis of the side chain of glutamine to produce ammonia is carried out by a 
glutaminase (GLNase) enzymatic activity associated with the CPSase (Simmer et al., 1990). 
The next step in de novo synthesis of pyrimidines is catalyzed by aspartate 
transcarbamoylase (ATCase), which condensates CP and aspartate (Asp) to form carbamoyl 
aspartate (CAsp) and Pi. Then, CAsp cyclizes to form dihydroorotate by the action of the 
zinc-metalloenzyme dihydroorotase (DHOase).  
 The next step in the pathway is the oxidation of the dihydroorotate to orotate by the 
enzyme dihydroorotate dehydrogenase (DHOdase). In eukaryotes, this enzyme is located at 
the inner mitochondrial membrane and couples the synthesis of pyrimidines to the 
mitochondrial electron transport chain (Bremer and Dennis, 1996, Rawls et al., 2000). Then, 
orotate is attached to the activated form of the ribose, PRPP, by the enzyme orotate 
phosphoribosyl transferase (OPRTase), to form the first pyrimidine nucleotide, orotidine 5-
phosphate (or orotydylate; OMP). OMP is then decarboxylated to form uridine 5-phosphate 
(uridylate; UMP) by the orotidylate decarboxylase (ODCase), considered one of the most 
catalytically efficient enzymes known (Radzicka and Wolfenden, 1995).  
 UMP is a major pyrimidine nucleotide, but it needs to be phosphorylated by ATP-
dependent kinases for the formation of the other major pyrimidines nucleotides. Thus, UMP 
is phosphorylated first to UDP by the UMP/CMP kinase, and later converted to UTP by the 
action of the nucleotide diphosphate kinase (NDK), an enzyme with a broad specificity that 
acts both on purines and pyrimidines. UTP is a precursor of RNA and can be considered the 
final product of de novo synthesis. The other pyrimidine for RNA synthesis, CTP, is obtained 
by the CTP synthetase, which uses ATP to activate a carbonyl oxygen of UTP, and then, 
replaces the phosphate by ammonia obtained by the hydrolysis of glutamine. 
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Figure 2. De novo biosynthesis of pyrimidines pathway in animals. De novo synthesis of UMP 
involves six reactions. In animals, the first three steps,  highlighted in a yellow box, are catalyzed by 
the multifunctional protein CAD. The fourth step is catalyzed by a dehydrogenase located in the inner 
mitochondrial membrane. The CPSase activity is the rate-limiting step of the pathway and is also 
allosterically inhibited by the final product, UTP, and activated by PRPP. The CPSase I is also shown 
in the mitochondrion, despite it is not involved in pyrimidine biosynthesis in animals. 
 
 Finally, the synthesis of DNA requires the reduction of the 2'-hydroxyl group of the 
nucleotides. These precursors are formed by the ribonucleotide reductase, an enzyme 
responsible for the reduction of the four di-phospho nucleotides to deoxyribonucleotides. In 
addition, uracile nucleotides need to be dimethylated to thymidine prior to its incorporation to 
DNA. This final step is carried out by the thymidylate synthetase that converts dUMP to 
dTMP, which is later phosphorylated by thymidylate kinase and NDK to form dTTP. 
 
2. Multifunctional proteins in de novo synthesis of pyrimidines 
 The six steps in de novo pathway leading to the synthesis of UMP are fully conserved 
in all living organisms. However, there is extensive diversity in the arrangement of the genes 
encoding the enzymes that catalyze these reactions, in the organization of the enzymes and 
in the regulation of the pathway (Jones, 1980). In prokaryotes, plants and most protozoa, the 
six enzymatic activities leading to the formation of UMP are encoded as distinct proteins, that 
either work alone or forming non-covalent complexes. In contrast, in animals, the six 
enzymes are encoded within just three polypeptides (Figure 3). 
 In 1971, the studies in mouse spleen carried out by Nicholas Hoogenraad and 
colleagues showed that the first two enzymes in de novo pathway, GLNase-dependent 
CPSase and ATCase, co-purified as a complex (Hoogenraad et al., 1971). Similar results 
had been previously described in yeast (Lue and Kaplan, 1969) and in molds (Williams et al., 
1970). Mary Ellen Jones also described that the complex in rat ascites cells additionally 
included the DHOase activity (Shoaf and Jones, 1971). The nature of this complex was not 
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truly understood until it was purified to homogeneity by George Stark and colleagues from a 
hamster cell strain treated with the ATCase inhibitor PALA (N-phosphonacetyl-L-aspartate) 
(Coleman et al., 1977) (see details in BOX 1). When the complex was isolated, the CPSase, 
ATCase and DHOase activities were found to be fused into a single polypeptide chain with a 
molecular mass of over 240 kDa (Figure 3A). The isolated protein was a mixture of different 
oligomeric forms, mainly trimers and hexamers, composed of multiple copies of the protein. 
The association of these three enzymes into a multifunctional polypeptide was subsequently 
documented in every animal species investigated and received various names, such as 
complex A or pyr1-3, rudimentary (in drosophila), or perplexed (zebrafish). Nowadays, this 
chimeric multi-functional protein is commonly known as CAD, an acronym derived from the 
initials of the three activities encoded within the polypeptide: (GLNase)CPSase, ATCase and 
DHOase. 
 
 
Figure 3. Organization of the three first enzymes of de novo pathway. (A) In animals, the first 
three steps are catalysed by the multifunctional protein CAD, shown schematically with each 
functional domain in a different colour. The CPSase activity is allosterically inhibited by UTP (in red) 
and activated by PRPP (in green). The phosphorylation sites and the residue numbers of the different 
domains are shown. (B) In fungi, e.g. S. cerevisiae, CPSase and ATCase are part of a multifunctional 
CAD-like protein that contains an inactive DHOase domain (pDHOase). The DHOase activity is 
provided by an independently encoded protein. (C) In bacteria, archaea and plants the enzymes 
function independently, although they can form either covalently or non-covalently linked complexes. 
In the case of E. coli, the ATCase forms a non-covalent complex with regulatory subunits (shown in 
yellow) that can be allosterically regulated. 
 Further studies led among others by the groups of David Evans, Jeffrey Davidson 
and Elizabeth Carrey helped to assign the enzymatic activities to independent functional 
domains within the CAD polypeptide. These studies relied on the extraordinary susceptibility 
of the protein to cleavage by specific proteases (Carrey and Hardie, 1988, Hemmens and 
Carrey, 1994, Davidson et al., 1981, Kim et al., 1992, Mally et al., 1981). The selective 
proteolytic cleavage and subsequent isolation of fragments retaining the enzymatic activities 
provided strong evidence for the domain structure of CAD, later verified by protein and gene 
sequencing (Carrey and Hardie, 1988) (Figure 3A).  
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BOX 1. PALA and the discovery of CAD. The discovery of CAD tracks back to the 70's, 
and is intimately ligated to the synthesis of PALA. Following Linus Pauling’s reasoning that 
analogs of the transition state would be potent reversible inhibitors of any enzymatic activity, 
Kim Collins and George Stark synthesized PALA, postulating that it would be a transition 
state analogue of ATCase (Collins and Stark, 1971). Indeed, PALA turn out to be a potent 
and specific inhibitor of E. coli ATCase.  
 
 
 
 
 
 
 
Figure 4. ATCase catalytic reaction and PALA. The tetrahedral intermediate state in the reaction is 
shown in brackets (Gouaux et al., 1987). PALA, shown in red, combines features of both substrates 
and resembles to some extent the transition state.  
 
 They also observed that PALA penetrated easily in mammalian cells cultures and 
mice, blocking de novo biosynthesis of pyrimidines and arresting cell proliferation. This assay 
demonstrated for the first time that de novo synthesis of pyrimidines was essential for cell 
growth and proliferation. However, a fraction of PALA-treated hamster CHO cells overcome 
the inhibitory effect by producing up to 150-fold higher levels of ATCase (Kempe et al., 
1976). Patrick Coleman and Parker Suttle used these PALA-resistant cells to isolate the 
mammalian ATCase, realizing that it co-purified forming a very stable complex with the 
CPSase and DHOase activities. Later on, they would discover that the three enzymes were 
covalently linked in a single giant polypeptide that they named CAD (Coleman et al., 1977) 
and that self-associated forming different oligomers, mainly trimers and hexamers. Further 
research by the group of Stark demonstrated that the PALA-resistant CHO cells underwent a 
massive amplification (up to 100-fold) of the cad gene (Wahl et al., 1979). This was the first 
evidence of gene amplification in mammalian cells, a common hallmark of cancer cells. 
 
  Interestingly, in fungi, GLN-CPSase and ATCase are also fused into a ~240 kDa 
CAD-like polypeptide (e.g. named URA2 in Saccharomyces cerevisiae) (Denis-Duphil and 
Kaplan, 1976), which contains a defective DHOase-like domain (Williams et al., 1970, 
Souciet et al., 1989). This activity is provided by a separated gene (URA4 in S. cerevisiae) 
encoding an independent and catalytically active DHOase (Guyonvarch et al., 1988).  
 CAD is not the only multi-functional protein found in de novo pyrimidine pathway in 
animals. In a similar manner, the reactions 5 and 6 in the pathway, catalyzed by OPRTase 
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and ODCase, depend on a bifunctional protein, the UMP synthase, which has evolved from 
the fusion of the two independent genes. This fusion also occurs in certain pathogens, 
although interestingly, in some instances, the order of the functional domains within the 
polypeptide is the reverse to that observed in animals (Traut and Jones, 1996). Enzymes 
catalyzing sequential reactions are commonly organized into macromolecular complexes. 
The assembly of enzymes into complexes offers advantages for improving the metabolic 
efficiency (see details in BOX 2).  
 
BOX 2. What are the advantages of a multi-functional protein? Multienzyme complexes 
can be composed of individual proteins that interact non-covalently, or they might result of a 
single polypeptide with several functional domains, such as CAD. The co-localization of 
different enzymes, by forming a multienzyme, favors the transfer of intermediates between 
the active sites without diffusion to the solvent, allowing the global coordination of the 
different activities. It also favors the forward direction of the reversible reactions, since 
products are taken by the next activity in the pathway, and also avoids the interference with 
other metabolic pathways in the cell. In eukaryotes, there are examples of these 
multifunctional polypeptides that must have been evolved by gene recombination. The 
number of the functional domains found in these multifunctional polypeptides can vary; for 
example, there are two in UMPS (Jones, 1980), two in tryptophan synthetase (Dunn et al., 
2008), two in acetyl-CoA carboxylase (Tran et al., 2015, Barber et al., 2005), three in CAD 
(four if we consider separately the GLNase domain), four in E. coli fatty acid oxidation a-
subunit (Yang and Schulz, 1983), five in the AROM complex in fungi (Hawkins et al., 1993), 
seven in animal fatty acid synthetase (Smith, 1994, Witkowski et al., 1991, Wakil, 1989), and 
up to ten in polyketide synthase (Dutta et al., 2014). The conservation of some of these 
fusions from yeast to humans implies that the multi-functional proteins may have additional 
selective advantages over the monofunctional prokaryotic counterparts and might reflect 
additional layers of complexity. What are these advantages? Encoding several proteins 
within a single transcript is the equivalent to a bacterial operon, a polycistronic messenger, 
with multiple translation initiation sites (Davidson et al., 1993, Coleman et al., 1977). Thus, 
gene fusions facilitate the production of proteins simultaneously and in stoichiometric 
amounts. The covalent linkage must enhance the association between the functional 
domains, which would otherwise diffuse freely and would depend on strong and highly 
specific interactions to assemble as a complex. These favored interactions might also 
increase the integrity of individual components, that would be unstable out of the complex. 
Furthermore, it is suggested that the order in which the genes are fused could be relevant for 
the folding and ordered assembly of the multifunctional complex (Marsh et al., 2013).  
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3. Cell growth, proliferation and regulation of de novo pathway by CAD 
 Pyrimidines are required for a wide variety of biological processes and are constantly 
made de novo in all cells. However, in de novo pathway each molecule of nucleotide is 
produced at high-energy price compare to salvage pathways, which are much more 
energetically efficient. This explains that the rate of de novo synthesis is reduced when 
exogenous uridine to feed the salvage pathway is supplied (Hoogenraad and Lee, 1974). In 
general, fully differentiated and quiescent cells obtain the supply of pyrimidines largely 
through salvage pathways, whereas the activity of de novo synthesis is in a low basal level. 
However, in rapidly growing and dividing cells the recycling route is not sufficient and the flux 
through de novo pathway is up-regulated to fuel the high demand of nucleotides needed for 
RNA and DNA synthesis, ribosome ribogenesis and other anabolic processes (Evans and 
Guy, 2004).  
 The mechanism of enzymatic regulation of de novo pyrimidine synthesis is different in 
prokaryotes and in higher eukaryotes (Figure 2 and 3). For instance, in bacteria, CP is the 
product of the first reaction in the pathway to make UMP, but it is also the substrate of others 
transcarbamoylases, such as ornithine transcarbamoylase (OTCase), which is involved in 
the biosynthesis of arginine. Thus, the first committed step to the biosynthesis of pyrimidines 
in prokaryotes is that catalyzed by ATCase, which is feedback inhibited by the final products 
of the pathway, CTP and UTP, and activated by the allosteric effector ATP (Kantrowitz, 
2012) (Figure 5). Contrary, in animals, the CPSase domain of CAD (CPSase II) catalyzes the 
dedicated production of CP for the synthesis of pyrimidines, being the limiting rate reaction of 
pathway. Thus, CPSase II is the control point of the pathway, being feedback inhibited by 
UTP and allosterically activated by PRPP (Liu et al., 1994) (Figure 3). Hence, unlike some 
bacteria, in animals, the ATCase domain of CAD is not subjected to a direct regulation by 
allosteric effectors. 
 The allosteric regulation of CPSase II by UTP and PRPP is further modulated by 
phosphorylation through two signaling cascades (Figure 3A). The mitogen-activated protein 
(MAP) kinase cascade (Erk1/2) phosphorylates CAD in residue Thr456, making CAD 
insensitive to feedback inhibition by UTP, converting UTP into a mild activator, and 
increasing the susceptibility of CAD to the activation by PRPP (Graves et al., 2000). CPSase 
II is also phosphorylated by cyclic AMP-dependent protein kinase (PKA) at Ser1406 (Carrey 
et al., 1985), resulting in a loss of feedback inhibition by UTP and in a decreased sensitivity 
to PRPP (Sahay et al., 1998). The phosphorylations by MAPK/ERK and PKA appear to be 
sequential and mutually exclusive during the life cycle of the cell, modulating CAD activity to 
satisfy the needs of pyrimidines during division (Sigoillot et al., 2003, Sigoillot et al., 2002). In 
this manner, when the resting cells are stimulated to proliferate, the MAP kinase cascade up-
regulates CAD activity by phosphorylating Thr456 just prior to the S-phase of the cell cycle, 
which results in an increased in the flux of the pathway and in the pyrimidine synthesis. 
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When cells come out of S-phase, Thr456 is dephosphorylated, and PKA phosphorylates 
Ser1406, turning CAD insensitive to the activation by PRPP and returning the flux of the 
pathway to resting levels.  
 Two recent independent studies have also demonstrated that CAD activity is also 
stimulated by phosphorylation through the mTORC1 (mechanistic target of rapamycin 
complex 1) pathway (Robitaille et al., 2013, Ben-Sahra et al., 2013) (Figure 3A). In response 
to nutrients, protein S6 kinase 1 (S6K) phosphorylates residue Ser1859 at the linker between 
the DHOase and ATCase domains (Robitaille et al., 2013, Ben-Sahra et al., 2013). This 
phosphorylation site is conserved among CAD sequences in vertebrates (Ben-Sahra et al., 
2013), and can also be phosphorylated in vitro by PKA (Carrey et al., 1985). The mTORC1-
dependent phosphorylation up-regulates the activity of CAD promoting pyrimidine synthesis 
and S phase progression. This phosphorylation also induces clustering of CAD in the 
cytoplasm and varies the sedimentation profile of the protein, suggesting that it promotes 
changes in the oligomerization of the protein (Robitaille et al., 2013).  
 CAD is also reported to autophosphorylate at residue Thr1037 (Carrey et al., 1985, 
Sigoillot et al., 2002). This leads to an increased sensitivity to UTP and loss of activation by 
PRPP. However, the level of autophosphorylation remains constant throughout the cell cycle 
and therefore, its significance is unclear (Sigoillot et al., 2003).  
 The activity of CAD is also regulated by its own synthesis and degradation. At the 
transcriptional level, CAD is regulated by Myc. The transcription of cad gene increases at the 
G1/S-phase boundary, when quiescent cells enter the proliferative cell cycle (Boyd and 
Farnham, 1997). This increase correlates with the c-myc expression peaks in dividing cells, 
which directly binds to the cad gene promoter (Huang and Graves, 2003). Contrary, c-myc 
expression is suppressed as cells exit the cell cycle or terminally differentiate, reducing the 
transcription of cad gene (Bush et al., 1998). On the other hand, CAD is rapidly broken down 
by caspase-mediated degradation during cell death, since it carries two caspase-3 cleavage 
sites located in CPSase domain (Huang and Graves, 2003).  
 
4. CAD in cancer and in other diseases 
 The up-regulation of CAD activity is essential for cell proliferation, particularly of 
tumors and neoplastic cells (Aoki and Weber, 1981, Sigoillot et al., 2004). Early studies 
demonstrated that the ATCase activity is 2 to 4-fold higher in hepatoma nodules than in 
adjacent liver tissue (Calva et al., 1959). Higher increments (up to 10-fold) in CPSase II 
activity were described in hepatomas when compared with normal liver (Aoki and Weber, 
1981). The activity of de novo pathway is increased 8-fold when BHK (baby hamster kidney) 
cells enter in exponential growth and drops sharply when the cells are confluent (Sigoillot et 
al., 2002). It has been also shown that the intracellular concentration of CAD is increased 3.5 
to 4-fold in MCF7 human breast cancer cells compared with normal cells, and remains 
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persistently activated along the cell-cycle (Sigoillot et al., 2004). This persistent activation 
correlates with the imbalance in the relative levels of Erk1/2 kinase and PKA activities in 
tumor cells (Sigoillot et al., 2004).  
 The up-regulation of CAD activity in malignant cells turns this multienzymatic protein 
into a potential anti-tumoral target for pharmacological intervention (Christopherson and 
Lyons, 1990, Christopherson et al., 2002, Löffler et al., 2005). However, only one anti-CAD 
compound, PALA, has been used in the clinic for cancer treatment (Collins and Stark, 1971, 
Johnson et al., 1976, Grem et al., 1988, Swyryd et al., 1974). A year before the discovery of 
CAD, in 1976, George Stark and colleagues tested the use of PALA as an antitumor agent in 
mice, with initial spectacular results (Johnson et al., 1976). They proved that PALA reduces 
the synthesis of pyrimidines (Yoshida et al., 1974, Swyryd et al., 1974) and effectively blocks 
the growth of different types of murine solid tumors (Grem et al., 1988, Tsuboi et al., 1977). 
In 1978, PALA was introduced into clinical trials (Grem et al., 1988) but failed to prove its 
efficacy as a single chemotherapeutic agent (Rosvold et al., 1992, O'Dwyer, 1990, O'Dwyer 
et al., 1990). Both in vivo and in vitro studies indicated that, at concentrations below 
cytotoxicity, PALA potently inhibits CAD and reduces UTP and CTP pools. Nevertheless, 
even at the highest doses tested, de novo synthesis was not reduced below 25 % of control 
(Grem et al., 1988). Then, emphasis was shifted to clinical application of PALA in 
combination with other drugs, such as 5-fluorouracil (a pyrimidine analogue). However, the 
combinational drug trials showed that UTP pools were reduced up to 60% but de novo 
biosynthesis pathway could not be completely blocked (Grem et al., 1988). Although the 
mechanisms of clinical resistance to PALA were not clearly defined, several hypotheses 
have been proposed. The resistance could arise from the amplification of the cad gene and 
overproduction of the protein in sufficient amounts to overcome the inhibitory concentrations 
of PALA (Christopherson and Jones, 1980). It has also been shown that PALA could 
stimulate the utilization of CTP and UTP by the salvage pathway (Kensler et al., 1980). 
Another explanation is related with CAD functioning, since a blockage of the ATCase activity 
by PALA would cause a local increase in CP concentration that could compete with the 
inhibitor and overcome the inhibitory effect (Christopherson and Duggleby, 1983).  
 CAD and the other activities in de novo pyrimidine pathway do not only have the 
potential as antitumoral targets, but also in the treatment of malaria and other parasitic 
infections (Löffler et al., 2005). The malarian parasite Plasmodium falciparum, and other 
pathogens, exhibit rapid nucleic acid synthesis during their intraerythrocytic growth phase 
(Gero et al., 1984). These parasites do not have pyrimidine salvage pathways and depend 
exclusively on de novo pathway (Seymour et al., 1994). In Plasmodium, the first enzymes in 
the route are not fused together as in CAD. This is an important distinct feature that could be 
explored for novel drug development. So far, synthetic ribozymes with specificity for the P. 
falciparum CPSase gene have shown potent inhibitory effects on the growth of cultured P. 
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falciparum parasites with no toxicity to mammalian cells (Flores et al., 1997). Similarly, de 
novo pyrimidine synthesis is essential for the infective growth of the protozoan Toxoplasma 
gondii. Mutants lacking the first enzyme or the last enzyme in the de novo pyrimidine 
biosynthetic pathway are not pathogenic in mice and cannot replicate in culture in the 
absence of uracil (Fox and Bzik, 2002). The monofunctional CPSase and DHOase enzymes 
of Toxoplasma show distinctive properties compared with the activity of CAD in the 
mammalian host cell, thus becoming potential targets for therapeutic intervention (Asai et al., 
1983).  
 The importance of de novo pyrimidines synthesis is also reflected in a number of 
syndromes and deficiencies associated with failures in distinct enzymes along the pathway 
(Ng et al., 2010, Suchi et al., 1997, Schwenger et al., 1993). However, until last year, there 
were no diseases directly attributed to a failure in CAD. Mutations in the cad gene in model 
organisms such as Drosophila melanogaster proved to be lethal when grown in pyrimidine-
deficient media. When supplemented with a diet rich in uridine and uracil, the flies survived 
but suffered severe developmental problems and females were sterile (NØRby, 1970, 
Conner and Rawls Jr, 1982). Mutations in CAD in Caenorhabditis elegans also associated 
with a 95% mortality of late-stage embryos (Franks et al., 2006) and with abnormalities in the 
surviving 5% of the worms. Again, this lethality was overcome by supplying a media with a 
rich content in uridine and uracil. Similarly, the mutations in CAD in zebrafish (named 
perplexed mutations) were reported to cause abnormal development and embryonic lethality 
(Cox et al., 2014, Willer et al., 2005). Overall, these results indicated that the mutations 
compromising the activity of CAD were lethal, and provided an explanation to the fact that no 
human diseases had been associated with defects in CAD. However, the group led by 
Hudson Freeze recently reported the first partial CAD deficit in a 4-year old patient with 
severe problems in protein glycosylation (Ng et al., 2015). The patient presented an 
abnormal splicing resulting in a 63 amino acid deletion, within the CPSase domain in one 
allele and a missense mutation, R2024Q, in the ATCase domain in the other allele. The 
metabolic studies showed that these mutations impaired the incorporation of aspartate into 
RNA and DNA, and severely decreased the levels of UTP, CTP and all UDP-activated 
sugars for glycosylation.  
 
5. The ATCase domain is key for the association of CAD into a 1.5 MDa particle 
 Despite the central role played in the metabolism of pyrimidines, the importance for 
cell proliferation and tumor development and the potential as a therapeutic target, by the time 
we started this study, there was a lack of detailed information about the architecture of CAD 
or about any of its functional domains. It was only known that this multifunctional polypeptide 
of ~240 kDa could self-assemble into ~1.5 MDa homo-hexamer, in equilibrium with other 
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oligomeric states such as trimers (Coleman et al., 1977, Lee et al., 1985, Qiu and Davidson, 
2000). 
  The DHOase and ATCase domains of CAD from hamster have been isolated 
following limited proteolysis of the full-length protein (Davidson and Patterson, 1979, 
Davidson et al., 1981, Mally et al., 1981, Kelly et al., 1986, Huang et al., 1999) and have 
been obtained recombinantly from E. coli by expression of cDNAs of various lengths (Huang 
et al., 1999, Davidson et al., 1993, Davidson and Niswander, 1983, Maley and Davidson, 
1988, Qiu and Davidson, 1998). It was not until 2014, when our group solved the crystal 
structure of the human DHOase domain that we had the first atomic glimpse of CAD 
(Grande-García et al., 2014, Lallous et al., 2012). This work also resulted in a revision that is 
presented as an appendix of this thesis (Ruiz-Ramos et al., 2015). 
 Many were the efforts to determine the crystal structure of the ATCase domain of 
CAD but with disappointing results (D. Evans personal communication). The group of Jeffrey 
Davidson proved that the recombinant ATCase domain of hamster CAD could complement 
the ATCase-deficient mammalian and bacteria cells, demonstrating that the ATCase domain 
of CAD is active when obtained separately from the other CAD domains (Davidson and 
Niswander, 1983, Major et al., 1989). It was also proven that the cleaved ATCase domain 
obtained by protease digestion or produced recombinantly formed homotrimers in solution 
(Grayson and Evans, 1983, Simmer et al., 1989, Qiu and Davidson, 1998), as described for 
all known bacterial ATCases (Shi et al., 2015). Davidson´s group also proved that the 
ATCase domain of CAD preserves specific interactions that were shown to stabilize the 
bacterial ATCase trimer (Qiu and Davidson, 1998). These conserved interactions were 
shown to be critical for the oligomerization of CAD since their disruption by site-directed 
mutagenesis (D90A or R269A) caused the dissociation of CAD hexameric particles (Qiu and 
Davidson, 2000). They also proved that the addition of the ATCase substrate, CP, or of the 
inhibitor PALA led to the re-association of CAD into hexamers (Qiu and Davidson, 2000). 
These results proved the key role of the ATCase domain for the assembly of CAD oligomers. 
  In the absence of a crystal structure of the ATCase domain of CAD, biochemical and 
modelling studies have supported the structural similarities with the E. coli ATCase catalytic 
subunits (Hemmens and Carrey, 1994, Scully and Evans, 1991, Maley and Davidson, 1988). 
The proposed similarity was further demonstrated by producing active chimeras that 
contained half of the ATCase domain of hamster CAD and half of E. coli ATCase catalytic 
subunit (Major et al., 1989).  
 
6. E. coli ATCase as the paradigm of the transcarbamoylase superfamily 
 The transcarbamylase family groups a large number of enzymes catalyzing the 
transfer of the carbamyl group from carbamoyl phosphate (CP) to a nitrogen or oxygen atom 
in a receptor substrate. These enzymes are involved in important metabolic pathways, such 
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as pyrimidine and arginine biosynthesis (Labedan et al., 1999), agmatine fermentation (Polo 
et al., 2012) and allantoin degradation (Bojanowski et al., 1964), among others.  
 ATCase (EC 2.1.3.2) and ornithine transcarbamoylase (OTCase; EC 2.1.3.3) are the 
best-known members of this family. The ATCase from E. coli (ecATCase) was the first family 
member for which the structure was determined (Honzatko et al., 1982). Indeed, ecATCase 
is probably one of the best structurally characterized enzymes, with more than 60 different 
crystal structures determined. In addition to the exhaustive structural characterization, the 
ATCase from E. coli has been widely studied biochemically, becoming a textbook model to 
explain allosterism (Monod et al., 1965) and cooperativity mechanisms (Perutz, 1989).  
 The quaternary structure of the ecATCase is a dodecamer composed by two catalytic 
trimers bridged non-covalently face to face by three regulatory dimers (Gerhart and 
Schachman, 1965, Honzatko et al., 1982). The enzyme exists in two different structural and 
functional states: the low-activity, low-affinity T-state and the high-activity, high-affinity R-
state (Figure 5A) (Changeux and Rubin, 1968). The conversation of the ecATCase 
holoenzyme from the T to R state occurs upon Asp binding to the holoenzyme in the 
presence of CP, The inhibitor PALA and ATP also trigger this T>R conversion (Gerhart and 
Pardee, 1962, Howlett and Schachman, 1977, Collins and Stark, 1971). Contrary, the CTP 
and UTP, the final product of de novo pathway, shift the equilibrium of the holoenzyme to the 
T-state (Gerhart and Pardee, 1962, Gouaux et al., 1990, Gerhart and Pardee, 1963). This 
T>R allosteric transition involves an elongation of the molecule of 11 Å along the three-fold 
axis, a relative rotation of 12º between the catalytic trimers and a 15º rotation of each 
regulatory dimer around their two-fold axis (Figure 5A) (Kantrowitz, 2012, Shi et al., 2015). 
The dissociation of the holoenzyme by heat treatment or with mercurial compounds results in 
more active catalytic trimers with non-cooperative active sites and no response to allosteric 
regulators. The isolated regulatory dimers binds nucleotide effectors but are catalytically 
inactive (Gibbons et al., 1974). 
 The ecATCase holoenzyme dissociation revealed that the functional unit of all 
transcarbamylases is a homotrimer with a concave triangular shape (Figure 5). Each subunit 
is divided into two similar domains. The N-terminal domains are involved in the binding of 
CP, therefore named N-domain or CP-domain, and are closer to the 3-fold axis of the trimer. 
The C-terminal domains protrude from the centre of the trimer and bind the second 
substrate. In the case of ATCase, this second substrate corresponds to aspartate (Asp) and 
is thus called Asp-domain. Both domains fold similarly, with a central parallel b-strand 
surrounded by a-helices connected by two additional transversal a-helices (Shi et al., 2015) 
(Figure 5). The active sites are located at the concave (bottom) face of the trimer, in a cleft 
formed between the two domains with residues from adjacent subunits (Jin et al., 1999) 
(Figure 5C). The binding of the substrates is ordered in all anabolic transcarbamoylases (Shi 
et al., 2015). CP binds in the first place to the N-domain, inducing the closure of a loop 
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(named loop 80s) from the adjacent subunit (Figure 5). Movement of the loop 80s interacts 
over the CP prepares the binding site for Asp (Wang et al., 2005). Upon Asp binding, a 
second loop from the C-domain (loop 240s) closes over the active site interacting with Asp 
and with the CP-domain (Figure 5) (Yuan et al., 1996). Releasing of the products is also 
order, delivering first the carbamoyl-aspartate (CAsp) and then, the inorganic phosphate. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of the ATCases quaternary organization and allosteric 
transition in E. coli ATCase. (A) E. coli ATCase holoenzyme (Class B). The catalytic trimer is shown 
in purple, whereas the regulatory dimers are shown in yellow. The allosteric transition to the low and 
high activity conformations are shown below. (B) Representation of the A. aeolicus ATCase 
holoenzyme (Class A). The DHOase dimers are shown in brown. (C) Representation of the ATCase of 
B. subtilis (Class C). This simplest class does not interact with partners and lacks regulatory and 
allosteric properties. The crystal structure of one subunit of the E. coli ATCase trimer is shown bound 
to PALA in the active site. 
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 There are numerous crystal structures of ecATCase, either for the catalytic trimers 
alone (ecATCase-C3) or in complex with the regulatory subunits forming a holoenzyme 
(Kantrowitz, 2012, Kantrowitz and Lipscomb, 1990, Lipscomb and Kantrowitz, 2012, 
Schachman, 1987, Allewell, 1989).  
 The ATCases in prokaryotes and archaea can be classified into different groups 
depending on their quaternary structure and the interactions with other proteins (Bethell and 
Jones, 1969, Labedan et al., 2004) (Figure 5). ecATCase belongs to Class B, where two 
catalytic trimers associate through three regulatory dimers forming a dodecameric structure 
(Figure 5A). A particular case of Class B ATCase is that of Thermotoga maritima, where the 
regulatory and catalytic subunits are fused into a single polypeptide (Chen et al., 1998). A 
second type of ATCases (Class A) also exhibits a dodecameric arrangement, but the two 
catalytic trimers are connected by three dimers of DHOase. These DHOases can be active 
(e.g. Aquifex aeolicus; subclass A1) or inactive (e.g. Pseudomonas aeruginosa; subclass A2) 
(Figure 5B). In the case of A. aeolicus, it has been proven that the association with ATCase 
is necessary for the DHOase to be active (Ahuja et al., 2004). The third type (Class C) 
corresponds to the simplest form of ATCase, which is formed by isolated catalytic trimers 
with no interactions with any additional protein partners (e.g. Bacillus subtilis) (Stevens et al., 
1991) (Figure 5C). Similarly to the ecATCase-C3, the ATCases belonging to the Class C lack 
allosteric and cooperative mechanisms (Brabson and Switzer, 1975).  
 There are crystal structures available for ATCases belonging to either of the three 
classes in prokaryotes and archaea, with the current exception of subclass A2 (complex with 
inactive DHOases). However, we lack structural information about the eukaryotic ATCases. 
Despite the predicted similarity with prokaryotic counterparts (Scully and Evans, 1991), a 
detailed characterization of this domain in animals is important to understand the 
architecture, functioning and inhibition of CAD. 
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The general aim of this thesis is to characterize structurally and biochemically the aspartate 
transcarbamoylase domain of human CAD (huATCase). This global goal implies attaining the 
following particular objectives: 
 
1. Clone, express and purify the recombinant huATCase. 
2. Crystallize huATCase free of ligands and in complex with the inhibitor PALA. 
3. Determine the crystal structure of huATCase and to study at atomic level the 
interaction of the protein with the ligands. 
4. Characterize the kinetic parameters of the isolated huATCase. 
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El objetivo general de esta tesis es caracterizar de manera estructural y bioquímica el 
dominio aspartato transcarbamilasa de la proteína humana CAD (huATCasa). Para ello, se 
han de lograr los siguientes objetivos específicos: 
 
1. Clonar, expresar y purificar la proteína recombinante huATCasa. 
2. Cristalizar la huATCasa libre de ligandos y en complejo con el inhibidor PALA. 
3. Determinar la estructura cristalográfica de huATCasa y estudiar a nivel atómico la 
interacción de la proteína con los ligandos. 
4. Caracterizar los parámetros cinéticos del dominio aislado. 
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MATERIALS AND METHODS 
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1. Cloning of the ATCase domain of human CAD 
1.1. Gene amplification and digestion of expression vectors.  
 The cDNA of human CAD (UniProt P27708) was purchased from Open Biosystems 
(clone ID 5551082). The gene fragment covering the ATCase domain of CAD, residues 
1915–2225 (hereafter huATCase), was amplified by PCR using Deep Vent DNA Polymerase 
(New England Biolabs) and the oligos flanking-forward and flanking-reverse (Table 1). The 
PCR program consisted in an initial denaturalization step at 95 ºC for 2 min followed by 25 
cycles of denaturalization (95 ºC for 30 s), annealing (58 ºC for 1 min) and extension (72 ºC 
for 1 min) with a final extension step of 10 min at 72 ºC. Flanking primers contained specific 
regions (Table 1, highlighted in bold) homologous to the 5' and 3' arms of the linearized 
pOPIN-F and pOPIN-M expression vectors (Oxford Protein Production Facility; 
https://www.oppf.rc-harwell.ac.uk/OPPF/). The expression vectors were linearized by 
digestion with the restriction enzymes KpnI and HindIII at 37 ºC for 3.5 h in buffer NEB 1 
(Berrow et al., 2007). This buffer is optimized for KpnI, and thus, we added and excess of 
enzyme HindIII during the double digestion of the plasmids. The linearized vectors and the 
PCR amplified gene were loaded on 1 % agarose gels, and the corresponding bands were 
visualized by staining with Gel-Red (Biotium Inc.), excised and purified using QIAquick Gel 
Extraction kit (QIAGEN).  
 
Table 1. Oligos used in huATCase cloning and site-directed mutagenesis. Adaptors for In-Fusion 
cloning are shown in italic and bold. The mutated triplets are shown in red.  
Construct Type Sequence (5´à 3´) 
WT 
Flanking- 
Forward AAGTTCTGTTTCAGGGCCCGATGTCACCCCTGCTGCACTCA 
Flanking- 
Reverse ATGGTCTAGAAAGCTTTAGAAACGGCCCAGCACGGT 
E1954A Forward ATGATGGTGCAGAAGGCGCGGAGCCTCGACATCC Reverse GGATGTCGAGGCTCCGCGCCTTCTGCACCATCAT 
D1958A Forward AAGGAGCGGAGCCTCGAGATCCTGAAGGGGAAGG Reverse CCTTCCCCTTCAGGATCTCGAGGCTCCG CTCC 
R2024Q Forward GTCGTCGTGCTCCAGCACCCCCAGCCTGG Reverse CCAGGCTGGGGGTGCTGGAGCACGACGAC 
 
1.2. In-Fusion cloning.  
 All the gene constructs in this work were made by ligation-independent cloning using 
In-Fusion HD cloning kit (Clontech Laboratories) (Figure 6). This technology allows a fast 
and directed insertion of a fragment of DNA in any vector by recombination of 15 bp 
overlapping regions (Table 1, highlighted in bold). The pOPIN vector suite is designed for the 
insertion of a single PCR amplicon flanked by the proper adaptors into a number of vectors 
that add different fusion tags to either the N- or C-termini of the protein. In particular, the 
chosen pOPIN-F and pOPIN-M vectors introduce a His6-tag or a His6-maltose binding protein 
(MBP) tag, respectively, at the N-terminus of huATCase. This technology, which is not limited 
by the presence of undesired restriction sites within the gene of interest, is particularly 
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convenient for cloning of long DNA fragments such as full-length CAD or the bi-functional 
DHOase-ATCase construct (see materials and methods, section 10.1.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Scheme of the In-Fusion 
cloning protocol. The expression 
vector is linearized by KpnI and HindIII 
restriction enzymes. The N-terminal 
sequence of the vector corresponds to 
the PreScission cleavage site (in blue). 
The vector extremes are sequence 
complementary to the ends of the PCR 
product, which are inserted by 
engineering the flanking oligos. Both, 
vector and PCR product, are mixed in 
the In-Fusion reaction, where the 
recombinase inserts the PCR product 
inside the vector. The reaction is 
directly used for transformation of E. 
coli TOP10 cells.  
 
 In general, the In-Fusion reaction was carried out at a 3-fold excess molar ratio of 
insert and vector, fixing the vector amount to a minimum of 100 ng per reaction. The mixture 
was incubated for 15 min at 50 ºC and 2.5 µl were transformed straight away in chemo-
competent E. coli TOP10 cells by heat-shock (Inoue et al., 1990). A quick screen of bacteria 
colonies containing the plasmid was carried by PCR. For this, a fraction of the grown 
colonies was picked with a pipette tip and transferred to a PCR tube with 12.5 µl of sterile 
water, which was subsequently heated at 95 ºC for 10 min. Then, 12.5 µl of a 2X PCR 
mixture containing a 5' primer for the vector and a 3' primer for the gene (flanking-reverse) 
was added to the sample and the PCR was performed as previously described. The positives 
colonies were detected by the visualization of an amplified band of the expected size in a 1 
% agarose gel. The positive colonies were re-picked and grown in media for plasmid 
purification (mini-prep). The correct cloning of huATCase gene within pOPIN-F (F-huATC) 
and pOPIN-M (M-huATC) was verified by sequencing of the complete gene and the 
corresponding flanking sequences. 
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1.3. Site-directed mutagenesis  
 huATCase single-point mutations E1954A, D1958A and R2024Q were made by 
directed-mutagenesis using the “overlapping extension PCR” method (Ho et al., 1989) 
(Figure 7). Firstly, two independent PCR reactions (PCR I and PCR II) were performed using 
a flanking primer (flanking-forward or flanking-reverse) and internal primers with the desired 
mutations (Table 1). The PCR program consisted in an initial denaturalization step at 98 ºC 
for 5 min followed by 30 cycles of denaturalization (95 ºC, 30 s), annealing (58 ºC, 45 s) and 
extension (72 ºC, 1 min) with a final extension step at 72 ºC for 5min. The PCR products 
were purified from a 1 % agarose gel using the QIAquick Gel Extraction Kit (QIAGEN) and 
applied as templates for a third PCR reaction (PCR III) with the primers flanking-forward and 
flanking-reverse. The products resulting from this PCR III were gel-purified and cloned in the 
linearized pOPIN-M using In-Fusion. The presence of the mutation and the absence of other 
undesired mutations were verified by gene sequencing. 
 
  
 
 
 
Figure 7. Site-directed mutagenesis 
protocol. This protocol involves two 
separated PCR reactions (PCR I and 
PCR II) to amplify the gene from the ends 
to the mutation region. The crosses 
indicate the point mutation. The PCR 
fragments are gel-purified and used as 
template for a third PCR reaction (PCR 
III) using both flanking oligos. The 
mutated PCR product contains the 
extensions for In-Fusion cloning (shown 
in blue and yellow). 
 
2. Production of the ATCase domain of human CAD 
2.1. Protein expression  
 E. coli BL21 (DE3) pLysS cells (Novagen) transformed with F-huATCase and M-
huATCase plasmids were grown in Luria-Bertani (LB) liquid media, supplemented with 100 
mg ml-1 ampicillin, at 37 ºC in a shaking incubator (220 rpm) to a density of OD = 0.6 - 0.8. 
Then, protein expression was induced with 1 mM isopropyl-b-D-thiogalactopyranoside 
(IPTG), and cultures were grown for six hours at 37 ºC before to harvesting by centrifugation. 
Alternatively, prior to the addition of the IPTG, the cultures were chilled in an ice-water bath 
for 10 min, and expression was performed overnight at 18-20 ºC.  
 Protein expression was also carried out by auto-induction in high density cultures 
(Studier, 2005). Briefly, a transformed colony of E. coli BL21 (DE3) pLysS cell was grown in 
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50 ml ZY-0.8G (Table 2) medium supplemented with 100 mg ml-1 ampicillin and 34 mg ml-1 
chloramphenicol for 16 hours at 37 ºC in a shaking incubator (220 rpm). Next day, 1 L of ZY-
5052 medium (Table 2), supplemented with the same antibiotics, was inoculated with 20 ml 
of the overnight pre-culture and grown for 6 hours at 37 ºC at 220 rpm. Then, temperature 
was decreased to 20 ºC for 20 h. Cells were harvested by centrifugation in a Beckman 
Coulter Avanti J-20 XP centrifuge using 1 L polypropylene bottles, washed with phosphate-
buffered saline (PBS), flash-frozen and stored at -80ºC.  
 
Table 2. Autoinduction media components.  
Stock solutions ZY-0.8G Final concentration ZY-5052 Final concentration 
ZYa To make up volume To make up volume 
1M MgSO4 1 mM 1 mM 
20% glucose 0.8 % - 
50x 5052b - 1x 
20x NPSc - 1x 
Ampicillin 100 µg/ml 100 µg/ml 
Chloramphenicol 34 µg/ml 34 µg/ml 
a ZY medium (10 g bactotryptone, 5 g yeast extract in 1 L distilled water). 
b 50x 5052 solution (25 % glycerol, 2.5 % glucose, 10 % α-lactose). 
c 20x NPS solution [1 M Na2HPO4, 1 M KH2PO4, 0.5 M (NH4)2SO4]. 
 
2.2. Protein purification  
 The cells were thawed and resuspended in chilled buffer A (20 mM Tris–HCl pH 8, 
0.5 M NaCl, 10 mM imidazole, 5% glycerol, 2 mM β-mercaptoethanol; 10 ml of buffer per mg 
of cell paste) complemented with 2 mM phenylmethanesulfonylfluoride (PMSF) and disrupted 
by sonication using a Vibra-Cell 75042 sonicator (Bioblock Scientific). The lysate was 
clarified by centrifugation at 40,000 rpm for 40 min at 4 ºC using a Beckman Coulter Optima 
XL-100K ultracentrifuge and a Beckman 45 Ti rotor. The supernatant was passed through a 
0.45 µm pore filter and applied onto a 5 ml Ni2+-loaded HisTrap Chelating FF column (GE 
Healthcare, USA) using a peristaltic pump at a flow-rate of 1 ml min-1. After loading, the 
column was connected to an ÄKTA Prime or a FPLC Purifier (both from GE-Healthcare). 
Following extensive washing of the column with 20 column volumes of buffer A containing 34 
mM imidazole, the protein was eluted step-wise with buffer A supplemented with 250 mM 
imidazole. The sample was diluted to 1.3 mg ml-1 with buffer S (20 mM Tris–HCl pH 7, 75 
mM NaCl, 5% glycerol, 2 mM β-mercaptoethanol) to prevent protein precipitation and 
dialyzed overnight against the same buffer. During this step, the fusion tag was cleaved off 
by inclusion of Prescission protease (1/20th of the protein weight) in the dialysis bag. The 
dialyzed and cleaved sample was loaded on a 5 ml HiTrap SP HP column connected to a 5 
ml GSTrap FF column (both from GE Healthcare, USA), both pre-equilibrated in buffer S. 
huATCase was retained in the HiTrap SP column, whereas the GST-tagged PreScission 
protease was retained in the GSTrap column and both the His6-MBP tag and the undigested 
huATCase passed through both columns. Then, huATCase was eluted at 110 mM NaCl in a 
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linear gradient of salt. The fractions containing the protein were pooled and loaded directly 
on a 5 ml HiTrap Heparin column (GE Healthcare, USA) pre-equilibrated in buffer S. Then, 
huATCase eluted in a NaCl gradient at 330 mM. The protein was concentrated to 3-5 mg ml-1 
in an Amicon Ultra system with a 30-kDa cutoff membrane. At this step, the protein could be 
conserved by adding 30% dimethyl sulfoxide (DMSO) and 5% glycerol, flash-frozen in liquid 
nitrogen and stored at -80 ºC. As a last purification step, the sample was further purified by 
size-exclusion chromatography on a Superdex 200 10/300 column (GE Healthcare, USA) 
pre-equilibrated in buffer GF [20 mM Tris- acetate pH 8.3, 0.15 M NaCl, 2% glycerol, 0.2 mM 
tris(2-carboxyethyl)phosphine (TCEP)]. huATCase eluted as a single peak that was 
concentrated to 3 mg ml-1 by ultracentrifugation. All purification steps were carried out at 4 ºC 
to preserve protein activity and to prevent degradation. Sample purity was evaluated by 
SDS–PAGE and Coomassie staining. Since huATCase has a low theoretical extinction 
coefficient (11920 M-1 cm-1) due to the lack of tryptophan residues, protein concentration was 
measured by Bradford method (Bradford, 1976) using the Bio-Rad Protein Assay Dye. 
 huATCase-D1958A mutant was purified as the wild-type (WT) protein. In turn, mutant 
E1954A eluted from the S-column in a broad peak along the salt gradient and thus, to avoid 
excessive protein dilution, the elution was done step-wise with 500 mM of salt. The fractions 
containing the huATCase-E1954A were pooled and diluted with dilution buffer (20 mM Tris-
HCl pH7, 5 % glycerol and 2 mM β-ME) to a final NaCl concentration of 250 mM. Then, the 
sample was loaded into the heparin column and followed the regular protocol. On the other 
hand, the solubility of mutant R2024Q in buffer S containing 75 mM NaCl was low, and thus, 
a second Ni2+-affinity column replaced the ion-exchange chromatography step. huATCase-
R2024Q eluted from the first Ni2+-affinity column was digested and dialysed against buffer A. 
Then, the sample was passed through a second Ni2+-affinity column, equilibrated in buffer A, 
from which the digested huATCase-R2024Q eluted by increasing the imidazole 
concentration to 34 mM. Then, the sample was diluted with dilution buffer to a final 
concentration of 150 mM NaCl and applied to the heparin column. R2024Q mutant eluted 
from the heparin column at 220 mM NaCl and purification continued as for the WT. 
 
2.3. Production of GST- PreScission protease 
 The pGEX-4-T plasmid containing the PreScission protease gene –also called HRV 
3C protease– was a kind gift of John Kuriyan (University of California, Berkeley, USA). This 
plasmid allows the expression of the protease N-terminal tagged to a glutathione S-
transferase (GST) removable by thrombin cleavage. The plasmid was transformed into E. 
coli BL21 (DE3) pLysS cells. A 50 ml LB pre-culture supplemented with 100 mg ml-1 
ampicillin and 34 mg ml-1 chloramphenicol was inoculated with one colony and grown 
overnight at 37 ºC. 20 mL of pre-culture were inoculated in 1 L of LB medium supplemented 
with the antibiotics and grown at 37 ºC until reaching a OD600= 1.0. Then, the culture was 
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quickly chilled for 10 min in an ice-water bath. The culture was grown for an additional hour 
at 20 ºC and then, protein expression was induced with 0.5 mM IPTG for 16 h at 20 ºC. Cells 
were harvested by centrifugation, washed with PBS and stored at -80 ºC.  
 For protein purification, the cell paste was resuspended in lysis buffer (1X PBS, 1 mM 
DTT and 5 mM EDTA; 5 ml per mg of cell paste; without adding any protease inhibitor). Cells 
were lysed by sonication and clarified by centrifugation at 40,000 rpm for 30 minutes. The 
supernatant was filtered and loaded twice in a 5 ml GSTrap FF column (GE Healthcare, 
USA) at 1 ml min-1 using a Peristaltic pump. The column was washed with 200 ml of lysis 
buffer, and the GST-tagged PreScission protease was eluted with 10 ml of 20 mM reduced-
glutathione pH 7.2. The eluted protein was dialyzed against buffer Q (20 mM Tris-HCl pH 8, 
150 mM NaCl and 1mM DTT) and loaded into a 5 ml HiTrap Q HP column (GE Healthcare, 
USA) pre-equilibrated in the same buffer. The protease did not bind to the column, and was 
concentrated to ~1.5 mg ml-1 using an Amicon with a 30-KDa cutoff membrane. Then, the 
concentrated protein was supplemented with 20 % glycerol, flash-frozen in liquid nitrogen 
and stored at -80ºC ready to use. All purification steps were carried out at 4 ºC. 
 
3. Size-exclusion chromatography coupled to multi-angle light-scattering (SEC-MALS) 
measurements  
 For molar-mass determination, we used 400 µl of purified huATCase wild-type 
(huATCase-WT) and of E1954A and D1958A mutants at 1.4 mg ml-1. Proteins were 
fractionated by gel filtration on a Superdex 200 10/300 column pre-equilibrated with buffer 
GF using an ÄKTA purifier at a flow-rate of 0.5 ml min-1. For huATCase-WT and huATCase-
D1958A, fractions corresponding to the first half of the peak (~2 ml) were pooled and re-
injected at a concentration of 0.25 mg ml-1, whereas mutant E1954A was re-injected at 0.16 
mg ml-1. The mutant huATCase-R2024Q was injected at 1.1 mg ml-1 and no re-injection was 
performed. In all cases, the eluted sample was characterized by in-line measurement of the 
refractive index and multi-angle light scattering using Optilab T-rEX and DAWN 8+ 
instruments (Wyatt Technology), respectively. Data analysis was performed using the 
ASTRA 6 software (Wyatt Technology) to obtain the molar mass (Wyatt, 1993). The program 
GraphPad Prism was used for graphical representation.  
 
4. Sedimentation velocity measurements  
 Analytical ultracentrifugation (AUC) studies were performed by J. R. Luque-Ortega at 
the Unidad de Ultracentrifugación Analítica y Dispersión del Luz - Centro de Investigaciones 
Biológicas (CIB-CSIC). Sedimentation velocity runs were carried out at 48,000 rpm and 20 
ºC in an XL-I analytical ultracentrifuge (Beckman-Coulter, Inc.) equipped with UV-visible and 
Raleigh interference detection systems, using an An-50 Ti rotor and 12-mm double sector 
centerpieces. The experiments were performed with huATCase-WT, huATCase-E1954A and 
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huATCase-D1958A samples. Prior to measurements, protein buffer was exchanged to 20 
mM Tris-HCl pH 8.3, 0.15 M NaCl, 1 % glycerol and 0.1 mM TCEP by dialysis. The 
concentrations of huATCase-WT tested were 1.4, 0.4, 0.1, 0.06 and 0.03 mg·ml-1 (40.2, 11.5, 
2.9, 1.7 and 0.1 µM). The concentrations of huATCase-E1954A were 1.0, 0.5, 0.38, 0.25, 
0.13, 0.06 and 0.03 mg·ml-1 (28.7, 14.3, 10.9, 7.2, 3.7, 1.8 and 0.9 µM). For huATCase-
D1958A the concentrations were 2, 1, 0.5, 0.25, 0.125, 0.06, 0.03 mg·ml-1 (57.4, 28.7, 14.3, 
7.2, 3.6, 1.8 and 0.9 µM). Sedimentation profiles were registered by absorbance at 230 nm. 
The sedimentation coefficient distributions were calculated by least squares boundary 
modelling of sedimentation velocity data using c(s) method as implemented in SEDFIT 
(Schuck, 2000). Measurements were normalized to obtain the percentage of trimers and 
monomers at each protein concentration. The program GraphPad Prism was used for 
graphical representation.  
  
5. Thermal shift assays 
 Thermal stability experiments were carried out using a 7300 Real-Time PCR System 
(Applied Biosystems). Two types of experiments were performed to characterize the 
huATCase-WT and mutants: pH buffer screening and substrate-induced stability. For pH 
screening, the pH Buffer Screen (Emerald Bio) was used as an additive screen. It contains 
12 different buffer systems at 8 different pH points, from 2.4 to 11.6. Each reaction contained 
2 μM huATCase protein, 200 mM NaCl, 2% glycerol, 2.5x SYPRO Orange (Invitrogen) and 
50 mM pH additive buffer in a final volume of 40 μl. The samples were dispensed in a 
MicroAmp optical 96-well reaction plate (Applied Biosystems) and sealed with an optical 
adhesive film (Applied Biosystems). Fluorescence intensity changes were monitored by 
increasing the temperature ramp by 1 ºC per minute from 20 ºC to 95 ºC.  
 Ligand-induced stability was tested in 40 µl reactions containing 1 μM huATC, 20 mM 
Tris-acetate pH 8.3, 100 mM NaCl, 2% glycerol, 2.5x SYPRO Orange and CP or PALA at 
concentrations ranging from 4 µM to 1 mM. Asp and succinate (Suc) were tested up to 30 
mM. PALA (CAS 51231-79-0) was obtained from the Developmental Therapeutics Program 
(NCI, National Institutes of Health) Open Chemical Repository. Data were processed and 
analysed with an Excel script (ftp://ftp.sgc.ox.ac.uk/pub/biophysics) (Niesen et al., 2007) and 
plotted with GraphPad Prism software. 
 
6. Enzymatic assays  
6.1. Substrate saturation assays 
 huATCase activity was assayed by a colorimetric method for carbamoyl-aspartate 
(CAsp) quantification (Prescott and Jones, 1969) adapted to a 96-well plate format (Else and 
Hervé, 1990). The materials used for the reaction included: 
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• Carbamoyl phosphate (CP): the CP stocks were prepared at 50 mM by dissolving 
lithium carbamoyl phosphate dibasic hydrate (Sigma-Aldrich) in chilled water and 
flash-frozen immediately. CP aliquots were stored at -20 ºC and thawed on ice for 
single use right before performing the experiments. 
• L-Aspartic acid (L-Asp): Asp (Sigma Aldrich) was dissolved in water at 300 mM final 
concentration. pH was adjusted to 8.3 with NaOH. L-Asp solution can be stored at 4 
ºC for one week.  
• Carbamoyl-L-aspartate (L-CAsp): L-CAsp (Bachem) was dissolved in water at 200 
mM final concentration and stored at -20 ºC. To perform the standard curve, L-CAsp 
was diluted at 2mM with 50 mM Tris-acetate pH 8.3 buffer.  
• N-(phosphonacetyl)-L-Aspartate (PALA): PALA (CAS 51321-79-0) was obtained from 
the Developmental Therapeutics Program (NCI, National Institutes of Health) Open 
Chemical Repository. The PALA stock was prepared at 100 mM in water and pH was 
adjusted to 7 with NaOH. PALA aliquots were stored at -20 ºC.  
• Succinate (Suc): Succinate (Sigma Aldrich) was dissolved in water at 0.5 M final 
concentration. pH was adjusted to 8.4 with NaOH. Suc stock was stored at 4 ºC for 
one week. 
• Colour mix solution: Colour mix consist of two parts of reagent A (0.37% antipyrine 
and 0.25% ammonium iron(III) sulfate in 25% H2SO4 95% and 25% H3PO4 85%) and 
one part of reagent B (0.4% diacetylmonoxime in 7.5% NaCl) (Nuzum and 
Snodgrass, 1976). The two reagents were gently mixed right before usage, and 
stored at 4 ºC in the dark until added to the reaction. 
• Protein samples: reactions were performed with 0.04 μM huATCase WT, 0.04µM 
D1958A mutant, 0.08 μM E1954A mutant and 0.4 μM R2024Q mutant.  
 
 Reactions were carried out at 25 ºC in 50 mM Tris-acetate pH 8.3 and 0.1 mg ml-1 
bovine serum albumin (BSA) in a final volume of 150 μl (Stebbins and Kantrowitz, 1989). In 
general, huATCase was pre-incubated with Asp for 10 min in a 96-well plate floating in a 
water bath at 25 ºC. The reaction was then triggered by adding CP. Substrate saturation 
experiments were done varying one substrate concentration while keeping the other fixed (10 
mM Asp or 5 mM CP). Asp concentration varied between 0 and 30 mM, while CP varied from 
0 to 10 mM. Reactions were stopped after 5 min by addition of 100 µl of colour mix solution 
(Else and Hervé, 1990). The plate was sealed with adhesive plastic and boiled at 95 ºC for 
15 min to allow colour developing (LM Polo, personal communication). Then, the plate was 
cooled down in the dark for 30 min. After a short spinning of the plate, absorbance was 
measured at 450 nm in a Victor 1420 Multilabel Counter (Perkin Elmer). A standard colour 
curve was performed with serial dilutions of L-CAsp in 150 µl of final volume in the same 96-
well plate as the titration assays. The process of colour developing and measurements was 
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carried out as already explained for titration assays. Data analysis was performed with 
GraphPad Prism software. huATCase activity was defined as mmol of CAsp synthetized per 
hour per milligram of protein.  
 Activity assays were also carried out in presence of the inhibitor PALA. In this case, 
the protein was pre-incubated with increasing concentrations of PALA (0 to 0.2 µM) and Asp 
for 10 min at 25 ºC. Reaction was triggered by adding CP. Asp and CP concentrations were 
the same used in substrate saturation experiments. Reactions were stopped after 5 min with 
colour mix solution. To test whether PALA is a slow-tight binding inhibitor, activity assays 
were performed at increasing stoichiometric concentrations of huATCase and PALA, ranging 
from 0 to 0.4 µM. The reaction was stopped at different times, up to 10 min, and colour was 
developed and measured as explained. Additionally, activity assays were performed at PALA 
concentrations up to 100 µM and at fixed 10 mM Asp concentration. Reaction was triggered 
with 5 mM CP and stopped after 5 min with colour mix reaction.  
Alternatively, to substrate saturation experiments, huATCase was pre-incubated with PALA 
and varying CP concentrations for 30 min at 4 ºC. After the incubation for 10 min at 25 ºC, 
the reaction was triggered by adding 10 mM Asp and stopped after 5 min by adding 100 µl of 
colour mix solution. The colour was developed and measured as explained. 
 Succinate activation assays were performed by pre-incubating the protein with Asp at 
sub-saturating concentration (0.2, 0.5 and 1 mM) and succinate (from 0 to 25 mM) for 10 min 
at 25 ºC. The reaction was triggered with 5 mM CP and stopped after 5 min with colour mix 
solution. Colour was developed and measured as explained.  
   
7. Isothermal titration calorimetry (ITC) 
 Isothermal titration calorimetry (ITC) studies were performed by Adrián Velazquez-
Campoy at the Institute of Biocomputational and Physics of Complex Systems (BIFI). 
Experiments were performed in an Auto-ITC200 calorimeter (MicroCal, GE Healthcare) at 15 
ºC. Calibration and performance tests of the calorimeter were carried out conducting Ca2+-
EDTA titrations with solutions provided by the manufacturer. The reaction cell contained 200 
µl of protein at 30- 40 µM in buffer GF. Titration experiments consisted on 19 injections of 2 
µl of PALA or CP at 0.4 mM and 1 mM, respectively. To measure CP binding in presence of 
succinate (Suc), the protein was pre-mixed with 2 mM Suc in the cell. All solutions were 
prepared in buffer GF and degassed before titrations. Titrant was injected at appropriate time 
intervals to ensure that the thermal power signal returned to the baseline prior to the 
injection. To achieve homogeneous mixing in the cell, the stirring speed was kept constant at 
1,000 rpm. The results were measured by the heat per injection normalized per mol of 
injectant versus molar ratio. The data were analysed with Origin 7 (OriginLab) using one-site 
and two-site binding models (Moreno-Beltrán et al., 2015).  
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8. Crystallization 
8.1. Optimization of huATCase crystals  
 High-throughput crystallization trials of huATCase were performed using a Cartesian 
MicroSys robot (Genomic Solutions), by the sitting-drop vapour-diffusion method in 96-well 
MRC plates. Nanodrops consisting of 0.2 μl of freshly purified protein plus 0.2 μl of reservoir 
solution were equilibrated against 60 μl of reservoir solution. Preliminary screening involved 
different protein concentrations and the following commercial crystallization screens: The 
JCSG+, PACT, Protein Complex, pHClear and pHClear II Suites (all from Qiagen). Plates 
were placed in a Rock Imager at 18 ºC and crystal growth was monitored using the Rock 
Maker software (Formulatrix). Initial hits were optimized manually varying the protein and 
precipitant concentrations, as well as the pH, in 15-well plates (Qiagen) with hanging drops 
consisting of 1 μl of protein solution and 1 μl of reservoir solution. Optimized crystallization 
condition for huATCase free of ligands consisted of protein at 1.5 mg ml-1 in GF buffer and 
0.1 M Tris pH 8.5, 6% PEG 8000 and 9% ethylene glycol (EG) as mother liquor at 18 ºC. 
Free-ligand crystals were cryo-protected by gradual increasing the EG up to 30% and frozen 
in liquid nitrogen for subsequent diffraction studies.  
 
8.2. Co-crystallization of huATCase and PALA 
 To crystallize the protein with the inhibitor PALA, huATCase at 3 mg ml-1 in buffer GF 
was diluted with an equal volume of 0.1 M CAPS pH 10 and 0.15 M NaCl to change pH and 
prevent protein precipitation upon PALA binding. PALA was added to a final concentration of 
0.5 mM and incubated on ice for ~30 min. Then, the sample was centrifuged for 10 min at 
13,000 rpm and used for crystallization. Optimal condition for the co-crystallization with PALA 
was obtained using 10 mM ZnCl2, 15% PEG 6000 and 50 mM sodium acetate pH 4.8 as 
mother liquor at 18 ºC. Prior to cooling in liquid nitrogen, the PALA crystals were transferred 
to mother liquor supplemented with 20% glycerol for cryo-protection. 
 
8.3. Soaking of huATCase crystals with CP 
 huATCase crystals free of ligands grown at a protein concentration of 1.73 mg ml-1 in 
similar conditions as described above (0.1 M Tris pH 8.5, 6% PEG 8000, 11% EG) and were 
soaked in 50 μl of mother solution supplemented with 5 mM CP for 5 min. Crystals were 
quickly cryoprotected in the same solution supplemented with 30 % EG and flash-frozen in 
liquid nitrogen.  
 
9. Data collection and structure determination. 
 X-ray diffraction data were collected at 100 K on beamlines PX-I (SLS synchrotron, 
Villigen) and XALOC (ALBA synchrotron, Barcelona) using Pilatus 6M detectors. Data 
processing and scaling were performed with XDS (Kabsch, 2010). Analysis of the intensity 
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distribution and statistics were performed with phenix.xtriage from the PHENIX package 
(Adams et al., 2010). Crystallographic phases were determined by molecular replacement 
using PHASER (McCoy et al., 2007). The model was built with Coot (Emsley et al., 2010) 
and refined with PHENIX (Adams et al., 2010). Validation of the model was determined with 
MolProbity (Chen et al., 2010).  
 
10. Production of the bifunctional human DHOase-ATCase construct  
10.1. Cloning and site-directed mutagenesis  
 The gene fragment covering the DHOase and ATCase domains of human CAD, and 
the 91 aminoacids inter-domain linker (huDHOaseATCase; residues 1456–2225) was 
amplified by PCR using the oligos flanking-forward and flanking-reverse (Table 3) and cloned 
in pOPIN-F using In-Fusion as previously described (section 1.1). Giving the large size of the 
insert (2,310 bp), the PCR extension time was lengthened to 2 min, with a final extension 
step of 10 min. Site-directed mutagenesis was carried out also as described in section 1.3. 
The pairs of oligonucleotides used to introduce the single-point mutation M1601E, D2009A, 
S1859D and S1859E are shown in Table 3. Wild-type and the mutated variants were verified 
by complete sequencing of the gene and flanking vector regions. 
 
Table 3. Oligos used in huDHOaseATCase cloning and site-directed mutagenesis. The adaptors 
for In-Fusion cloning are shown in italic and bold. The mutated triplets are shown in red.  
Construct Type Sequence (5´à 3´) 
WT 
Flanking- 
Forward AAGTTCTGTTTCAGGGCCCGATGACCTCCCAAAAGCTTGTG 
Flanking- 
Reverse ATGGTCTAGAAAGCTTTAGAAACGGCCCAGCACGGT 
M1601E Forward GCTGCTGTCCTCGAGGTGGCTCAGCTC Reverse GAGCTGAGCCACCTCGAGGACAGCAGC 
D2009A Forward GGCGAATCCCTGGCTGCCTCCGTGCAGACCATG Reverse CATGGTCTGCACGGAGGCAGCCAGGGATTCGCC 
S1859D Forward CGAATCCATCGAGCCGATGACCCAGGTTTGCCAGC Reverse GCTGGCAAACCTGGGTCATCGGCTCGATGGATTCG 
S1859E Forward CGAATCCATCGAGCCGAAGACCCAGGTTTGCCAGC Reverse GCTGGCAAACCTGGGTCTTCGGCTCGATGGATTCG 
 
10.2. Protein expression in HEK293 cells 
 huDHOaseATCase wild-type (huDHOaseATCase-WT) and the mutants were 
expressed in HEK293S GnTI- cells grown in 1 L suspension cultures in FreeStyle medium 
(Invitrogen) supplemented with 1% fetal bovine serum (Aricescu et al., 2006) at 37 ºC and 
5% CO2 in an orbital shaker at 135 rpm. Cultures were divided into two baffled polycarbonate 
Erlenmeyer flasks (CORNING) with 2 L capacity for better aeration. Cells were transfected at 
a density of 1.5 million cells ml-1 by adding 50 ml of a 1:3 ratio mixture of DNA plasmid and 
polyethylenimine (PEI 25 kDa branched; Sigma). Prior to the transfection, the DNA and PEI 
were diluted to 20 and 60 mg ml-1, respectively, in UltraDOMA medium (Lonza) and 
incubated for 5 minutes at room temperature. Then, the solutions were mixed together and 
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incubated for 10 min at room temperature before adding the mixture to the cells. After the 
transfection, the cells were grown for 2–3 days and then, harvested by centrifugation. The 
cell pellet was washed with PBS and store at -80ºC. 
 
10.3. Protein purification  
 The cells were resuspended in 50 ml of chilled buffer A supplemented with 3 mM b-
ME, 2 mM PMSF, 1 µM leupeptin and 1 µM pepstain A. Cells were disrupted in a chilled 
glass Dounce tissue grinder, followed by 3 min sonication (pulses of 3 s and 1 s breaks). The 
clarified supernatant was loaded onto a 5 ml Ni2+ HisTrap Chelating FF column (GE 
Healthcare, USA) using a peristaltic pump. Following extensive column washing of 30 
column volumes with buffer A containing 60 mM imidazole, the protein was eluted with buffer 
supplemented with 300 mM imidazole. Fractions containing the eluted protein were pooled 
and dialysed overnight against buffer D (20 mM Tris-HCl pH8, 0.5 M NaCl, 5% glycerol, 40 
mM imidazole and 2 mM b-ME). PreScission protease was added in the dialysis bag to 
cleave off the His6-tag. After dialysis, the protein was centrifuged at 4,000 rpm for 10 min to 
eliminate the precipitate, filtered and loaded into a 5 ml Ni2+ HisTrap Chelating FF column 
attached to a GSTrap FF column (GE Healthcare, USA) and pre-equilibrated in buffer D. The 
digested huDHOaseATCase protein did not bind to these columns, and was pooled and 
concentrated up to 1.5 mg ml-1 in an Amicon Ultrasystem with a 30K cutoff membrane. As a 
final step, the protein was loaded into a Superdex 200 10/300 pre-equilibrated in buffer GF2 
(20 mM Tris-HCl pH 8, 0.3 M NaCl, 5 % glycerol and 0.1 mM TCEP). The elution peak was 
concentrated as before, supplemented with 20% glycerol, flash-frozen in liquid nitrogen and 
stored at -80 ºC. 
 
11. SEC-MALS analysis  
 Molar-mass determination was carried out as previously described in section 3. 400 
µl of purified protein at approximately 1 mg ml-1 were fractionated in a Superose 6 10/300 
column equilibrated in buffer GF2 using an ÄKTA purifier at a flow-rate of 0.5 ml min-1. 
huDHOaseATCase-WT was first injected at 1.72 mg ml-1 and the 250 µl fraction 
corresponding to the maximum of the peak (fraction E2) was re-injected at a concentration of 
0.32 mg ml-1. The mutants M1601E, D2009A, S1859D and S1859E were applied to the 
column at 0.9, 1.0, 1.2 mg ml-1 and 1.1 mg ml-1, respectively. Mutants were not re-injected in 
the column. The eluted samples were characterized by in-line measurement of the refractive 
index and multi-angle light scattering using Optilab T-rEX and DAWN 8+ instruments (Wyatt 
Technology), respectively. Data analysis was performed using the ASTRA 6 software (Wyatt 
Technology) to obtain the molar mass (Wyatt, 1993). The program GraphPad Prism was 
used for graphical representation.  
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1. The ATCase domain of human CAD can be produced recombinantly 
1.1. Cloning of human ATCase domain 
 Based on sequence comparison with bacterial homologues and on previous work on 
hamster CAD by the group of Jeffrey Davidson (Maley and Davidson, 1988, Major et al., 
1989), we mapped the ATCase domain within human CAD, starting in residue S1915 and 
ending at F2225, the most C-terminal CAD residue (Figure 8). The corresponding region of 
the human cad gene (nucleotides 5768 to 6704) was amplified by PCR and inserted in two 
expression vectors from the pOPIN series (Oxford Protein Production Facility (Berrow et al., 
2007)) using the ligase independent In-Fusion technology. In particular, we selected the dual 
vectors pOPIN-F and pOPIN-M, which allow the expression both in bacteria and in 
mammalian cell cultures. pOPIN-F introduces a His6-tag at the N-terminus of the protein, 
whereas pOPIN-M adds an N-terminal His6-tagged maltose binding protein (MBP). Both 
gene constructs include a PreScission protease site that allows the selective cleavage of the 
genetic tag. PreScission is a versatile engineered human rhinovirus 3C protease fused to the 
glutathione S-transferase protein (GST) that works very effectively at low temperature and 
under conditions of high ionic strength or high glycerol. The usage of this protease is also 
convenient since it can be produced inexpensively in the laboratory (BOX 3). 
 
 
 
 
Figure 8. Sequence alignment of C-terminal human CAD and E. coli catalytic subunit. The 
analysis was performed in the Clustal Omega webserver. The sequences share 44% identity.  
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BOX 3. Purification of PreScission protease. PreScission protease was induced by the 
addition of the IPTG at 20 ºC for 16 h. We noticed that to express the protein at low 
temperature is important, since at 37 ºC the production yield is better but the protein 
becomes inactive. The band of the overexpressed protein was clearly observed in the 
supernatant (Figure 9). The protease was purified by two-step produce involving a 
glutathione column (GSTrap) and an ion-exchange column. To minimize protein degradation, 
all the purification steps were performed at 4 ºC. The protein eluted from the GSTrap column 
is around 15 - 20 mg of total protein per liter of cell induced. Although the sample seems to 
elute almost pure, a second chromatography step was needed. Thus, the sample eluted from 
the GSTrap was dialyzed for 16 h to change the buffer and increasing the NaCl 
concentration. PreScission protease did not bind the ion-exchange column and eluted in the 
flowthrough. The contaminants were retained in the column. Pure protein was concentrated 
up to 1 mg ml-1 and supplement with glycerol prior freezing in liquid nitrogen and stored in 
250 µl aliquots at -80 ºC.  
 
 
 
 
 
1.2. Protein expression 
 We tested the expression of the huATCase constructs in two different E. coli strains: 
Rosetta(DE3) and BL21(DE3). The transformation of pOPIN-F and pOPIN-M vectors, even 
without any inserted gene, strongly inhibited the growth of lysogenic DE3 bacteria. This effect 
was palliated by using pLysS strains and media supplemented with glucose, suggesting that 
the toxicity problem could be related to an undesired strong activation of the lac promoter 
and leaky protein expression. Both Rossetta pLysS and BL21 pLysS cells produced soluble 
protein at similar levels and were used at convenience during the course of this work. 
Alternatively, we also express of the two protein constructs in HEK293 GnTI-cells. This 
particular cell line has a mutation in the N-acetyl-glucosaminyltransferase I that reduces the 
branching of polysaccharides in the cell surface and facilitates the growth in suspension 
(Aricescu et al., 2006). By using either bacteria or HEK293 cells, we observed that the N-
terminal fusion to the MBP is key for the expression and solubility of the protein (Figure 10). 
Since E. coli produces larger amounts of recombinant protein than HEK293 cells and it is 
also faster, cheaper and easier to scale up, we selected bacteria as the system of choice for 
Figure 9. Purification steps monitored by 
Coomassie-stained SDS-PAGE (12%). St, 
standards of molecular weight; L, lysate; S, 
supernatant; F, flowthrough; W, wash; E1, elution 
from GStrap; E2, elution from ion-exchange.
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the production and isolation of huATCase. Initially, the protein was expressed in bacteria 
inducing with IPTG (data not shown). Later on, we changed to an autoinduction expression 
protocol (Studier, 2005) to increase the volume and density of the cultures and thus, obtain 
larger amounts of recombinant protein. 
Figure 10. Expression of huATCase in HEK293 cells. Analysis by 12% SDS-PAGE of a small-scale 
(50ml) production of His6-huATCase (~38 kDa) (A) and His6-MBP-huATCase (~80 kDa) (B). The cells 
expressing the protein were lysated (L) and the clarified supernatant (S) was incubated with Ni2+-
chelating resin. The non-bound sample (flowthrough, F) and the washes with 10, 30 and 50 mM 
imidazole (W1–W3) do not contain the protein of interest. The elution (E) of the protein from the beads 
with 250 mM imidazole shows that only the MBP fused protein is produced. Protein standards are 
indicated (in kDa). The black dots indicate the expected migration of the huATCase proteins. 
 
1.3. huATCase purification 
 We devised and optimized a purification protocol to isolate huATCase that included 
four chromatography steps: Ni2+-affinity, anion-exchange, heparin and size-exclusion (Figure 
10A-D). The overexpressed protein was clearly observed by SDS-PAGE both in the lysate 
supernatant and in the eluted fractions from the Ni2+-affinity column (Figure 11E). The 
estimated molecular mass of the protein band was around 80 KDa (Figure 10E, lane ENi), in 
good agreement with the expected theoretical size (79.85 KDa). At this step, the average 
yield was of approximately 50 mg of total protein per litre of bacterial culture, out of which we 
estimated that more than 80% corresponded to MBP-huATCase. The sample was then 
dialysed overnight to eliminate the imidazole, and at the same time, PreScission protease 
was added inside the dialysis bag to cleave the His6-MBP-tag. After removal of the tag, three 
extra residues remained at the N-terminus of huATCase (GPMS1915). The cleaved MBP, 
which proved to be key for the expression of huATCase, turns into a major contaminant of 
the preparation (Figure 11E, lane D). The second Ni2+-column step or the usage of an 
amylose resin were insufficient to get rid of the MBP tag. In turn, the introduction of an anion-
exchange chromatography proved to be a very effective purification step. huATCase binds to 
the column and elutes in a salt gradient nearly pure, with the sole exception of a contaminant 
of ~20 kDa (Figure 11E, lane ES). This contaminant is highly soluble compared to huATCase 
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and due to the losses of huATCase protein during the subsequent concentration steps, the 
contaminant can reach up to 20 % of the total protein in the sample, which was clearly 
undesirable for crystallization studies. Mass-spectrometry analysis (carried out at the CNIO 
Proteomic Unit) identified the contaminant as E. coli catabolite activator protein (CAP; also 
known as cAMP receptor protein; UniProt P0ACJ8), a well-known DNA-binding protein. 
Thus, we introduced as an additional purification step a heparin column to which CAP bound 
tighter than huATCase (Figure 11C). After this step, huATCase appeared >98% pure (Figure 
11E, lane EH) and was concentrated and injected onto a size-exclusion chromatography 
column, the final step of purification. huATCase eluted as a single and sharp peak with no 
aggregates appearing at the void volume of the column (Figure 11D). The fractions 
corresponding to the huATCase peak were pooled and concentrated to approximately 3–5 
mg ml-1. The final yield of the purification was 10 mg of pure protein per litre of cell culture.  
 The purified huATCase was initially flash-frozen in liquid nitrogen with no cryo-
protectant or supplemented with 40% glycerol and then, stored at -80 ºC. However, we 
noticed that the specific activity of the protein after three-weeks storage decay up to 2-fold 
(data not shown). Previous work on purified hamster CAD, reported that the sample was 
frozen with 30% DMSO (v/v) and 5% glycerol (w/v) (Coleman et al., 1977). This freezing 
condition proved to be effective also for huATCase, which preserved the activity up to two 
months after storage at -80 ºC. All the experiments described in this work were performed 
with freshly purified sample or with protein frozen in DMSO/glycerol and stored at -80 ºC for 
less than one month.  
 
2. huATCase forms homotrimers in solution  
 The purified huATCase migrated on a SDS-PAGE at the expected molecular weight 
of 35 kDa (Figure 11E-F). Contrary, the protein eluted from a size-exclusion column as a 
single peak at ~14.9 mL (Figure 11E), which according to the calibration with standards of 
known molecular weight, corresponded to a homotrimer with approximate mass of 110–125 
kDa (Figure 12A). To accurately measure the molecular mass of the oligomer, huATCase 
was injected at 1 mg ml-1 onto a size-exclusion column coupled to a multi-angle light 
scattering device (SEC-MALS). Light scattering measurements along the elution peak 
indicated the formation of a single species of average molecular mass 99.6 kDa (± 0.2%), in 
good agreement with the theoretical mass of the expected trimer (104.6 kDa) (Figure 12B).  
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Figure 11. huATCase purification. (A) Chromatogram of Ni2+-chelating HisTrap FF column. The blue 
line shows the elution profile monitored by UV absorption at 280 nm. The increase of imidazole in the 
buffer is indicated with a green line. Most contaminants do not bind to the column and flow through 
(FNi) or are washed away (WNi) with 34 mM imidazole. The protein, eluted in 250 mM imidazole (ENi), 
was dialyzed overnight in the presence of PreScission to reduce salt concentration and cleave the 
His6-MBP tag. (B) Chromatogram of a HiTrap SP column. The cleaved His6-MBP appears in the 
flowthrough (FS), whereas huATCase is eluted in a salt gradient (green line) at ~120 mM of NaCl (ES). 
(C) The eluted protein from HiTrap SP was directly loaded onto a heparin column equilibrated in buffer 
with 75 mM NaCl. huATCase and CAP bind to the column with different affinities and can be 
separated using a salt gradient, with huATCase eluting at 330 mM NaCl (EHep). (D) Chromatogram of 
size-exclusion chromatography (Superdex 75 16/600). The void volume at ~8 ml is indicated. (E) 
Purification steps monitored by Coomassie-stained SDS-PAGE (12%). L, cell lysate; S, clarified 
supernatant; D, dialyzed and digested with PreScission; other lanes are labelled as in previous panels. 
Protein molecular-weight markers are indicated on the left of the gel. (F) Plot of the electrophoretic 
mobility of protein markers used to estimate the molecular weight of huATCase. Abscissa axis is 
represented in log scale. Open circles correspond to molecular-weight markers, closed circles 
correspond to cleaved His6-MBP tag and E. coli CAP; huATCase is indicated with a red circle. 
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 Interestingly, we noticed that when the protein was injected at concentrations below 
0.5 mg ml-1, the elution peak showed a shoulder at ~16.9 ml. Initially, this was believed to 
correspond to the contaminating CAP protein, but as the purification protocol was optimized, 
the hypothesis that it might correspond to partial dissociation of the trimer gained weight. To 
test this possibility, the fractions from the first half of the peak corresponding to the trimer 
were pooled and re-injected in the size-exclusion column, and this procedure was repeated a 
second time. We observed that as the concentration of the re-injected sample decreased, the 
shoulder peak became more apparent (Figure 12C-D). The MALS analysis of this shoulder 
peak indicated a molecular mass of 39.7 (± 0.64%), in agreement with the expected size of 
the huATCase monomer. 
 
Figure 12. Determination of the oligomeric 
state of huATCase by SEC-MALS. (A) 
Semilogaritmic plot of the molecular mass versus 
the elution volume from a Superdex 75 gel 
filtration column. Closed circles indicate the 
elution volume of proteins standards (1, 
thyroglobulin; 2, ferritin; 3, aldolase; 4, 
conalbumin; 5, ovalbumin). The empty circle 
indicates the expected position for a huATCase 
homo-trimer (theoretical mass 105 kDa). The 
black trace shows the elution profile of huATCase 
from the column. (B) SEC-MALS analysis using a 
Superdex 200 column. Protein elution profile with 
the measurement of the differential refractive 
index (dRI; black trace; left axis) and the 
corresponding molar mass (red dots; right axis). 
The grey shades indicate the fractions of the 
peak that were pooled and re-injected in the 
column (B,C). The concentrations at which the 
protein was injected in the columns were: 1.4 mg 
ml-1 (B), 0.3 mg ml-1 (C), and 0.1 mg ml-1 (D). 
 
 
 
 
 We confirmed the dissociation of the 
huATCase trimer by analytical 
ultracentrifugation (AUC). Sedimentation 
velocity assays demonstrated the presence 
of two species with different hydrodynamic 
size and sedimentation coefficients (Figure 
13A-B). The most prominent species, 
sedimenting at 5.2 S, corresponded to a 
trimer of ~105 kDa, whereas a second 
species of 2.7-3 S agreed with a protein 
monomer of ~35 kDa. We measured the 
relative proportion of the monomer versus 
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trimer at different protein concentrations. The most diluted sample that could be accurately 
measured with the instrument had a concentration of 0.03 mg ml-1 (0.86 μM) and exhibited 
79 % of monomer. Plots of the relative percentage of trimer versus protein concentration 
fitted to a hyperbola from which we estimated a dissociation constant (KD) of 0.27 ± 0.04 µM 
(Figure 13C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Measurement of huATCase dissociation constant. (A) Sedimentation velocity profile at 
0.1 mg ml-1 huATCase measured by absorbance at 232 nm. The absorbance scan across the 
centrifuge cell is shown in different colors. In the first scan (grey color), the sedimentation of 
huATCase has already depleted its concentration in the region near the top of the tube and formed a 
sedimentation boundary. As the experiment progresses, the depleted region expands and the 
boundary moves away from the center of the rotor. By the end of the experiment (red color), the 
concentration of protein has dropped to essentially zero throughout the upper half of the cell. (B) 
Transformation of the data in (A) into a sedimentation coefficient distribution. The graph resembles a 
size-exclusion chromatogram (except that the peaks come in the opposite order), where the area 
under the peaks gives the relative amount of each species present in the sample. The apparent 
diffusion coefficient, calculated from the peak width, and the ratio of sedimentation coefficient to 
diffusion coefficient allow estimating the molecular mass of each species. (C) Graphical representation 
of the percentage of trimer measured at different protein concentrations. The data fit to a hyperbola 
(black line) from which a dissociation constant (KD) can be estimated. 
 
3. huATCase stability is enhanced by the binding of ligands  
 We used differential scanning fluorimetry (thermofluor) to test the stability of the 
protein at different pH values and with different ligands (Niesen et al., 2007). The 
temperature at which huATCase unfolds was measured in a quantitative PCR machine by 
the increase in fluorescence of SYBR orange that binds to exposed hydrophobic areas of the 
protein. In the absence of ligands, the transition temperature or temperature of melting (TM) 
of huATCase was within 50.6 – 54.8 ºC range at a pH between 6 and 9 (Figure 14A). 
Interestingly, the stability of the protein increased notably in phosphate buffer (TM = 70 ºC), 
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likely due to the binding of inorganic phosphate to the active site. Indeed, we observed that 
the stability of huATCase increased when CP was added to the sample, up to maximum TM 
of 70 ºC (Figure 14B). Titration of PALA caused an even higher stabilization of the 
huATCase, with a rise of the TM up to 83 ºC. Considering this increase in stability as a rough 
indicator of the binding of the ligands to the protein we estimated a high affinity for CP and 
PALA, with dissociation constants (KD) below 1 µM (Figure 14C). 
 Importantly, the addition of Asp in the absence of CP did not affect the stability of the 
protein (Figure 14B), suggesting that, as reported for other ATCases (Porter et al., 1969), the 
human enzyme also follows a compulsory order in the binding of the substrates. The addition 
of Asp to huATCase already bound to CP cannot be measured since the reaction would take 
place. Thus, we titrated an inert Asp analogue, succinate (Porter et al., 1969), to a pre-
incubated mixture of huATCase and CP. The combination of CP and succinate did not mimic 
the stabilizing effect of PALA (Figure 14B), indicating that the mixture of both ligands does 
not trigger a conformational change comparable to that with PALA, which likely explains the 
high stabilization of the protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. huATCase stability and ligand 
binding assessed by differential scanning 
fluorimetry. (A) huATCase melting temperature 
(TM) monitored by thermal shift assays at 
different buffer conditions. (B) Denaturing 
curves measured in buffer Tris-acetate pH 8.3 in 
the absence and presence of CP, Asp, 
succinate (Suc) and PALA. (C) Graphical 
representation of the increase in TM at varying 
concentration of CP or PALA. 
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4. huATCase exhibits positive cooperativity for the binding of substrates 
 The enzymatic activity of the isolated huATCase domain was determined by 
measuring the production of carbamoyl aspartate (CAsp) in a discontinuous colorimetric 
assay (Prescott and Jones, 1969) adapted to a 96-well plate format (Else and Hervé, 1990). 
Due to the low stability of CP when it is not bound to the enzyme (t1/2 of ~1h at 25 ºC) 
(Legrain et al., 1995), the reaction was started by the addition of CP to a pre-incubated 
mixture of huATCase and Asp (Stebbins et al., 1989). First, we estimated the initial rate and 
ensured that it was proportional to the total enzyme concentration. For this, we performed 
time-course experiments at 37 ºC with three different concentrations of huATCase and 10 
mM Asp and 5 mM CP (Figure 15A). The production of CAsp, calculated by interpolation in a 
standard curve prepared with L-CAsp (Figure 15B), progressed linearly up to approximately 
the consumption of 30 % of the CP in the reaction. According to these data, the reaction rate 
was proportional to the concentration of enzyme used and the velocity was calculated as 8 
mmol of CAsp produced per h and per mg of protein (Figure 15C). Further enzymatic assays 
were carried out with 0.04 µM of enzyme and stopped after 5 min. In addition, the 
temperature of the experiment was lowered to 25 ºC to compare the huATCase activity with 
those of bacterial homologues, mostly measured at this temperature (Stebbins et al., 1989). 
Figure 15. huATCase activity. (A) Time-course experiment at three different huATCase 
concentrations. (B) Standard curve of the absorbance of known concentrations of carbamoyl-L-
aspartate (CAsp). (C) The production of CAsp increases linearly with the concentration of enzyme. 
 
 Plots of initial rates at 25 ºC, measured at fix concentration of Asp (10 mM) and 
varying concentration of CP, followed a sigmoidal curve that fitted to the Hill equation with 
Vapp= 4.1 mmoles h-1 mg-1, [CP]0.5app = 0.2 mM and nH=1.6 (Figure 15A). The deviation from 
the Michaelis-Menten equation was better diagnosed in an Eadie-Hofstee plot (Figure 16A, 
inset). On the other hand, initial rates at 5 mM CP and varying concentration of Asp followed 
a complex trend (Figure 16B). Up to 7.5 mM Asp, the data fit a sigmoid with Vapp = 4.5 
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mmoles h-1 mg-1, [Asp]0.5app = 2.2 mM and nH = 1.3, whereas at higher concentrations, Asp 
has a pronounced inhibitory effect (Figure 16B, inset).  
Figure 16. Substrate saturation curves. (A) huATCase activity measured at 25 ºC by fixing the 
concentration of Asp (10 mM) and varying the concentration of CP. Fitting to a Hill equation (sigmoid; 
solid line) is more accurate than to a Michaelis-Menten equation (hyperbola; dashed grey line). (B) 
Activity assays at fixed concentrations of CP (5 mM) and varying the concentration of Asp. The data 
was fitted taking into account the inhibition at high Asp concentrations. The insets in both graphs show 
the Eadie-Hoffstee plot of the data to highlight the deviation from the Michaelis-Menten behaviour 
(dashed grey line). 
 
 Kinetic values of Vapp and S0.5 for huATCase are in the same order of magnitude to 
those observed for the isolated ATCase domain from hamster CAD (Qiu and Davidson, 
1998, Grayson and Evans, 1983). However, sigmoidicity in the kinetic curves indicates that 
huATCase exhibits positive cooperativity for the substrates. This means that binding of CP 
and Asp at one active site increases the substrate affinity and/or activity in the other subunits 
within the trimer. The cooperativity effect in huATCase was unexpected since the isolated 
catalytic trimer of bacterial ATCases lack the homotropic properties and are reported to be 
non-cooperative (Gerhart and Holoubek, 1967, Porter et al., 1969, Stebbins et al., 1989).  
 To further test the cooperativity effects on huATCase, we performed activity assays at 
sub-saturating Asp concentration in the presence of increasing concentrations of the 
competitive inhibitor succinate. It has been shown in in E. coli ATCase (Stebbins et al., 1989) 
that low succinate concentrations stimulate the activity by promoting the T-R transition, 
whereas at higher concentrations, succinate has an inhibitory effect. Contrary to ecATCase, 
we did not detect stimulation of the activity in presence of succinate (Figure 17). Succinate 
inhibits huATCase activity at the three Asp concentrations that were tested.  
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Figure 17. huATCase activity in the presence 
of succinate. Activity measured at 25 ºC at 
increasing concentrations of succinate in 5 mM 
CP and the following sub-saturating 
concentrations of Asp: (A) 0.2 mM, (B) 0.5 mM 
and (C) 1 mM. Insets, details at low succinate 
concentrations. 
 
 
 
5. huATCase binds PALA with negative cooperativity 
5.1. PALA strongly inhibits huATCase activity 
 To test the effect of PALA on huATCase activity, we performed substrate saturation 
curves triggering the reaction with CP at increasing concentrations of the inhibitor (Figure 
18A,B). huATCase activity is inhibited by PALA at substoichiometric concentrations -lower 
concentrations than those of the enzyme used in the reaction–, which agrees with the tight 
binding of the inhibitor described for E. coli ATCase (Collins and Stark, 1971, West et al., 
2008). The inhibition by PALA could not be overcome by raising the concentrations of any of 
the two substrates (Figure 18A,B), as if PALA was a non-competitive inhibitor of the reaction.  
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Figure 18. huATCase inhibition by PALA. (A) Cleland-diagram of the experimental setup. 
huATCase is pre-incubated with Asp and PALA and the reaction is started by addition of CP. (B,C) 
Saturation curves at increasing concentrations of PALA. (D) Time-course experiments in absence and 
presence of PALA. (E) Ackerman-Potter plot representing the activity of huATCase mixed with 
approximately stoichiometric concentrations of PALA. The prolonged linear section of the curves 
intersects with the abscissa axis, indicating the concentration of enzyme titrated out by PALA during 
the reaction, as represented in the inset. (F) Cleland diagram showing a different experimental setup, 
where the reaction is triggered by the addition of Asp. (G) CP saturation curves at increasing 
concentrations of PALA following the experimental setup in (F).  
 
 Time-course activity experiments in presence of PALA showed a lag in the linear 
formation of CAsp (Figure 18D). This indicated that, although the binding of PALA is 
reversible, its dissociation is a slow process compared to the binding of the substrates or the 
reaction turnover. Thus, PALA behaves as a “slow-tight binding inhibitor” (Morrison, 1969, 
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Morrison, 1982). Rather than being a non-competitive inhibitor, PALA binding sequesters the 
enzyme in an “inactive state” during most of the reaction time, causing an apparent reduction 
in Vapp, whereas the kinetic properties (S0.5app, kcat) of the free enzyme remained unchanged.  
 To further test whether PALA is a slow-tight binding inhibitor, we incubated 
huATCase and PALA at similar concentrations and measured the residual activity. The 
Ackermann-Potter plot in Figure 17E confirmed that PALA is a substoichiometric inhibitor, 
and the intersections of the prolonged linear portions of the curves with the abscissa axis 
indicate the amount of enzyme titrated out by the inhibitor during the reaction (Ackermann 
and Potter, 1949). 
 As a rough approximation to the steady-state, we pre-equilibrated the enzyme with 
CP and PALA and then, started the reaction by adding Asp (Figure 18F). Using this 
experimental set up, we observed that inhibition occurred at concentrations of PALA ~100-
fold higher than in the previous experiments. In this case, the inhibition was overcome by the 
increasing concentrations of CP, demonstrating that indeed, CP and PALA compete for the 
binding to the same form of the enzyme. Analysis of the data yielded a KiPALA = 351 nM. This 
high value is at odds with the tight stoichiometric binding, suggesting that this approach is not 
valid to quantify the interaction between huATCase and PALA. 
 Another intriguing result was that we failed to completely inhibit huATCase activity at 
the PALA concentrations tested (Figure 18B,C,G). This was likely due to the slow 
interchange of PALA with the large excess of CP present in the solution during the reaction 
time (Figure 18B). To attain full inhibition, we increased the concentration of PALA up to 100 
µM (Figure 19A). Notably, huATCase activity decreased with PALA concentration following a 
triple exponential decay, from which we estimated I50 values of 0.014 µM, 1.4 µM and 14 µM. 
This result was again in conflict with the knowledge about bacterial ATCases catalytic 
trimers, since it strongly suggested that huATCase trimer exhibits different affinities for the 
binding of the inhibitor. 
 
5.2. Quantification of CP and PALA binding by isothermal titration calorimetry 
 To accurately measure the binding of substrates and PALA to huATCase, we 
performed isothermal titration calorimetry (ITC) assays. We proved the existence of three 
independent and equivalent binding sites for CP per huATCase trimer, with a KDCP = 6.3 µM 
(Figure 19B). We failed to detect the binding of Asp or succinate to the protein alone. We 
neither observed the binding of succinate in a pre-incubated mixture of enzyme succinate. 
When higher concentrations of succinate were tested, the heat released by small differences 
in the pH between the sample in the cell and the injected solution of ligand masked any 
possible changes in enthalpy caused by the binding of the ligand (data not shown).  
 Surprisingly, the titrations with PALA proved the existence of three non-equivalent 
binding sites per huATCase trimer with increasing intrinsic dissociation constants KD1 = 0.017 
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µM, KD 2 = 0.027 µM and KD 3 = 1.4 µM (Figure 19C). This negative cooperativity for the 
binding of PALA, with nearly 100-fold difference in affinity between the first and third binding 
sites, was unexpected, since, as already mentioned, the isolated catalytic trimers of bacterial 
ATCases lack homotropic effects between the active sites. Further clarification required a 
detailed characterization of the huATCase structure. 
 
Figure 19 Measurements of PALA binding to 
huATCase. (A) Inactivation of huATCase at increasing 
concentrations of PALA follows a triple exponential 
decay. I50 values are indicated. (B,C) Calorimetric 
titrations for the interaction of huATCase with CP (B) or 
PALA (C). Upper plots show the thermogram (thermal 
power as a function of time) and lower plots show the 
binding isotherm (normalized heat per injection as a 
function of the molar ratio ligand:protein). Non-linear 
fitting analysis was performed considering three identical 
non-cooperative binding sites (B) or three non-identical 
cooperative binding sites (C). Intrinsic site-specific 
dissociation constants are indicated. 
 
 
6. huATCase crystallization  
6.1. Initial crystallization screening 
 huATCase crystallized at 18 ºC under a 
variety of conditions tested from commercial 
screenings. Most crystals appeared in conditions 
with 10-25 % polyethyleneglycol of different sizes as 
precipitant, 100-200 mM salt (most frequently 
MgCl2) and at pH values between 5 and 9. The 
conditions yielded a large number of small crystals 
that usually appeared overnight. The crystals were 
thin plates with approximate dimensions of 50 x 50 
µm, that most often clustered together. We 
exhaustively tried to reduce the nucleation and to 
increase the size and thickness of the crystals. 
However, neither the changes in the crystallization 
solutions, temperature or protein concentrations 
improved the number, size or morphology of the 
crystals. In turn, we found out that using freshly 
purified protein significantly reduced the amount of 
nucleation and resulted in slightly thicker crystals. 
On the contrary, the use of protein frozen before or 
after the gel-filtration step yielded poorer results in 
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the crystallization trials. Therefore, we purified and used it immediately to perform the 
crystallization experiments.  
 
6.2. Crystallization of huATCase free of ligands 
 Starting from the condition number 16 of the JCSG+ Suite as the initial hit, we 
optimized the crystallization of huATCase in absence of ligands to a final condition that 
contained 0.1 M Tris- HCl pH 8.5, 6% PEG 8000, 9% ethylene glycol (EG). The crystals were 
optimized in sitting drops by mixing equal volumes of reservoir and of freshly purified protein 
at 1.5 mg ml-1. The crystals appeared after 1–2 days at 18 ºC and grew without clustering 
(Figure 20A). Most of the crystals were thin plates with trapezoidal shape and 0.2 mm in the 
maximum dimension. In the same drops, similar thin but hexagonal-shaped crystals also 
appeared. These crystals exhibited concave faces, which has been suggested to be a 
possible indicator of crystal twinning (Yeates, 1997). Prior to cooling in liquid nitrogen, the 
trapezoidal crystals were transferred to a cryo-protectant solution supplemented with 30% 
EG. 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Crystallization of huATCase and X-
ray data collection. (A) Crystals of huATCase 
grown by the hanging-drop method in absence of 
ligands. The inset shows hexagonal-shaped 
crystals with an apparent concave face that 
appeared together with the more common 
trapezoidal-shaped crystals. The dotted line 
indicates the relation between the crystals types. 
(B) Rugby-ball-shaped crystals of huATCase 
grown in the presence of PALA. (C) X-ray 
diffraction pattern of huATCase crystal grown 
with PALA obtained from the XALOC beamline 
(ALBA). The circles indicate the resolution limits 
in Å. (D) Twinning analysis of the X-ray diffraction 
data of the crystals free or grown with PALA 
processed in space group P21. The L-test for 
acentric data indicates a deviation from the 
expected distribution for a normal untwinned 
crystal (Padilla and Yeates, 2003).  
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6.3. Crystal soaking in CP 
To obtain the crystal of the complex with CP, we used the method of soaking the apo crystals 
in mother liquor supplemented with CP. The incubation with the ligand had a visible 
damaging effect on the crystals that eventually dissolved. We attempted to optimize the 
concentration of the substrate and the incubation time to preserve the integrity of the 
crystals. By restricting the incubation time to 5 min in the solution containing 5 mM CP, some 
larger crystals appeared to be more resistant. These crystals were cryo-protected with 
solutions of increasing concentration of EG containing CP and flash-frozen for further 
diffraction studies. 
 
6.4. Co-crystallization of huATCase with PALA 
 To crystallize the protein in complex with PALA, we first mixed huATCase at 1.5 mg 
ml-1 with 0.5-1 mM PALA in buffer at pH 8. Under these conditions, a precipitated appeared 
after 30 min, and the remaining soluble protein fraction, at a concentration of 0.5 mg ml-1, did 
not form crystals. Since the reported crystals of bacterial ATCases in complex with PALA 
were mostly obtained in conditions with extreme acidic or basic pH, we changed the pH of 
the protein sample by adding buffer at pH 10 (CAPS) or 5.5 (MES) and then added PALA to 
a final concentration of 0.5 mM. In this way, the addition of PALA did not cause protein 
precipitation and the sample could be used for crystallization. Initial crystals of huATCase 
with PALA were obtained at 18 ºC in condition number 12 of the PACT Suite [0.1 M sodium 
acetate pH 5, 10 mM zinc chloride, 20% (w/v) PEG 6000]. Optimization of this condition 
allowed us to grow rugby-ball-shaped crystals with a maximal dimension of 80 µm (Figure 
20B). The final crystallization conditions were 50 mM sodium acetate pH 4.8, 10 mM zinc 
chloride, 15% PEG 6000, mixing huATCase at 3 mg ml-1 in gel-filtration buffer with an equal 
volume of 0.1 M CAPS pH 7, 150 mM sodium chloride and 1 mM PALA. The crystals were 
cryo-protected with 20% glycerol and flash-frozen in liquid nitrogen. 
 
7. huATCase structural determination 
7.1. X-ray diffraction data collection and processing 
 We used the in-house diffractometer to test that the crystals were indeed made of 
protein and that diffracted X-rays. All subsequent diffraction experiments were carried out 
using synchrotron radiation at SLS (Villigen), DESY (Hamburg) and ALBA (Barcelona). In 
general, the crystals diffracted X-rays poorly. The diffraction spectra were anisotropic and 
reached a maximum resolution of 4 Å in the best direction. A screening of approximately 
hundred crystals was needed to collect complete datasets of huATCase free of ligands 
(huATCase-apo), soaked with CP (huATCase-CP) or co-crystallized with PALA (huATCase-
PALA) at resolutions better than 3.2 Å (Figure 20C).  
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 Initial indexed reflections indicated that the three crystal types belonged to the 
hexagonal space group P6322, with similar unit-cell parameters a = b = 83 Å and c = 145–
158 Å. Matthews coefficient calculation predicted the presence of one huATCase protomer 
per asymmetric unit, with a VM of 2.35 Å3 Da-1 and a solvent content of 48%. Therefore, the 
threefold axis of the huATCase trimer was coincident with the crystallographic symmetry 
axis. However, analysis of the diffraction data with phenix.xtriage from the PHENIX package 
(Adams et al., 2010) indicated a significant deviation of the intensity statistics from the 
expected distribution and suggested the over-merging of pseudo-symmetric intensities. 
Reprocessing the diffraction data in lower symmetry space groups yielded significantly better 
statistics (Tables 4 and 5). It was possible that the crystals belonged to the monoclinic space 
group P21, with the peculiarity that the b angle was 120º. The predicted content of the 
monoclinic asymmetric unit was six huATCase subunits that would form two trimers. This 
unusual P21 unit-cell geometry allows pseudomerohedral twinning. Indeed, a subsequent L-
test analysis (Padilla and Yeates, 2003) of the X-ray diffraction intensity statistics of the three 
datasets diagnosed a deviation from the expected distribution of a normal untwinned crystal 
(Figure 20D). 
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7. 2. Structure determination 
 Crystallographic phases were obtained by molecular replacement using the catalytic 
chain of E. coli ATCase (PDB 2ATC) as the search model. Initially, we carried out the 
molecular replacement considering that the crystal belonged to the space group P6322, and 
we subsequently attempted to build and refine a model for one protein subunit within the 
asymmetric unit. Although the electron density maps allowed the tracing of most of the 
protein backbone, the refinement did not progress beyond unusually high values of R factor 
and Rfree that did not match the overall decent quality of the electron density maps. By 
reducing the symmetry of the space group to P21, we built and refined the structure of two 
protein trimers per asymmetric unit (Figure 21A). During the initial refinement cycles, non-
crystallographic symmetry restraints were maintained between the six subunits. The 
restraints were gradually released during the refinement as small differences were 
appreciated between the different subunits (Figure 21B). Even before the refinement was 
completed, it appeared clear that the huATCase molecule lacked a strict 3-fold symmetry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. huATCase trimers lack a strict three-fold symmetry. (A) Representation of the 
monoclinic asymmetric unit with six protein subunits forming two trimers. (B) The superposition of the 
preliminary models of the subunits within the trimers suggested clear deviations from a strict three-fold 
molecular symmetry. Most important differences localized at flexible regions, encircled with a dashed 
line. 
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The largest differences between the subunits were found in loops that appeared to be more 
flexible. The different orientations of some side chains were also clearly noticeable. These 
discrepancies between the independent chains in the crystal, which might indicate 
conformational flexibility in solution, explained the problems during model refinement 
considering P6322 as the space group, since the molecular three-fold axis is not a strict 
crystallographic axis. The models for huATCase-apo, huATCase-CP and huATCase-PALA 
were refined to final R/Rfree values of 15.0/17.2, 22.1/25.1 and 15.2/20.8, respectively. The 
refinement statistics are as given in Table 6.  
 
Table 4. Data collection and refinement statistics. 
 
huATCase-APO 
(PDB 5G1O) 
huATCase-CP 
(PDB 5G1P) 
huATCase-PALA 
 (PDB 5G1N) 
Data Collection    
Beamline PXI, SLS PXI, SLS XALOC, ALBA 
Wavelength (Å) 1.0 0.976 1.148 
Space group P21 P21 P21 
Unit cell 
a,b,c (Å) 
a, b, g (º) 
82.8, 157.9, 82.7 
90, 120, 90 
83.7, 157.7, 83.5 
90, 120, 90 
83.0, 145.1, 83.2 
90, 120, 90 
Resolution (Å) 42.4-2.1 (2.15-2.10)a 50-3.20 (3.28-3.20) 50-2.1 (2.15-2.10) 
Rmeas (%) 11.6 (60.7) 17.1 (77.6) 6.8 (60.2) 
I/sI 8.9 (2.4) 9.9 (2.3) 13.9 (2.5) 
Completeness (%) 94.3 (63.9) 99.4 (99.9) 98.0 (97.9) 
Redundancy 3.4 (2.9) 4.8 (4.9) 3.4 (3.4) 
CC1/2 98.9 (69.0) 99.0 (59.3) 99.8 (77.5) 
Refinement    
Resolution (Å) 42.43-2.10 42.54-3.2 41.58-2.10 
No. of reflections 95,831 29,277 92,437 
R factor/Rfree (%) 15.04/17.17 22.07/25.07 15.23/20.76 
Rmsd 
Bond lengths (Å) 
Bond angles (º) 
 
0.008 
1.284 
 
0.012 
1.64 
 
0.007 
1.268 
No. of atoms 
Protein + ligand 
Water 
 
13,605 
485 
 
13,098 
95 
 
14,238 
483 
Ramachandran plot 
Favored (%) 
Allowed (%) 
Outliers (%) 
 
93.10 
4.89 
2.01 
 
88.4 
8.24 
3.4 
 
94.14 
4.71 
1.15 
aValues in parenthesis correspond to the highest resolution shell. 
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8. Overall structure of huATCase 
 The molecular architecture of huATCase shares a common structural scaffold with 
bacterial ATCases and other enzymes of the transcarbamoylase superfamily. huATCase 
exhibits an equilateral triangular appearance, a dome-shaped 3-bladed propeller with active 
sites located at the concave or "bottom" face of the trimer (Figure 22). The radius from the 
center to the vertex of each subunit is roughly 50 Å, and the distance from the bottom to the 
top face is ~30 Å. Each subunit within the trimer is divided into two domains of similar size, 
nucleated by a central b-sheet of five parallel strands flanked by a-helices (Figure 22).  
 
 
Figure 22. Overall structure of huATCase trimer. Cartoon representation of huATCase trimer in 
apo-form (A) or bound to PALA (B). The trimers are shown in two perpendicular views. The central b-
sheets are colored in pink, with the helixes of the N- and C-domains colored in blue and green, 
respectively. The CP-loop is shown in yellow and the Asp-loop is colored orange. The huATCase-APO 
structure has a glycerol molecule bound within the central tunnel. In (B) the area delimiting each 
subunit in the trimer is marked out with a purple line. 
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 The two domains are interconnected by two a-helices –H5 and H12– running in 
opposite directions. The N-terminal domain (residues 1915-2056 and 2210-2225) is closer to 
the 3-fold axis, provides most of the contacts with the other subunits in the trimer and is 
responsible for the binding of CP (CP-domain) (Figures 21 and 22). The C-terminal domain 
(residues 2057–2209) occupies an external position at the vertices of the triangle, and holds 
the Asp binding site (Asp-domain).  
 The trimer has a central tunnel along the threefold axis, delimited by helix H2 and 
strand S3 from each subunit (Figure 22). The tunnel is 23 Å long and has a uniform radius of 
3-3.5 Å along the axis, except at the top entrance where it is partially occluded by the loops 
connecting helices H1 and strands S2 (hereafter named loop H1-S2) and at the bottom face 
near the active sites, where the entrance is flanked by the CP-loops. The electron density 
was unambiguous for most of the huATCase-apo polypeptide chains, except for two 
disordered loops comprising residues 1994-2003 (hereafter named as CP-loop and 
equivalent to loop 80s in ecATCase) and residues 2148-2163 (named Asp-loop and 
equivalent to loop 200s in ecATCase) (Figure 22A). The Asp-loop appeared well-ordered 
only in one out of the six huATCase-apo subunits (subunit F) due to contacts with adjacent 
subunits in the crystal lattice. As already mentioned, soaking with CP damaged the crystals, 
but at least for one of them we collected a dataset. This huATCase-CP crystal diffracted at 
lower resolution (Table 6) and, although the overall quality of the density maps did not allow 
a precise tracing of some regions, a molecule of CP was assigned in the extra electron 
density observed within the active site of every subunit. In this structure, the CP-loops are 
well-ordered and interact with the CP bound in the active site of an adjacent subunit. On the 
other hand, the Asp-loops are flexibly disordered as in huATCase-apo crystals (Figure 22A). 
In turn, both the CP- and Asp-loops were clearly defined in huATCase-PALA structure, 
where a molecule of inhibitor is bound in the active site of every subunit (Figure 22B). 
 As mentioned, in huATCase-apo structure, the CP-loop and the Asp-loop are mostly 
disordered and thus the bottom entrance of the tunnel appears wide-open in the crystal 
structure. This might explain the presence of a glycerol molecule within the tunnel, next to 
residues G1988 and G1999 in the loop connecting helix H2 and strand S3 (Figure 22A). 
Contrary, in huATCase-CP and huATCase-PALA the rearrangement of the CP-loops causes 
the partial closure of the bottom entrance of the tunnel and the glycerol molecule is not 
observed despites being included in the crystallization and cryo-protectant solutions. 
 
9. CP induces partial hinge-closure of the subunit and primes Asp binding 
 CP binds at the N-end of helix H2, with the phosphate group interacting with the main 
chain N atoms of residues T1974, R1975 and T1976, and with the side chains of T1976 and 
R2024 (Figures 23B and 24A). The carbamoyl moiety of CP interacts through the O atom 
with the side chains of T1976 and H2052, and through the N atom with the carbonyl O of 
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M2185 and with the side chain of Q2055. CP induces the positioning of the CP-loop from the 
adjacent subunit, which fits snuggly within the active site and binds to the CP through the 
side chain of S2000. The side chain of K2003 –at the tip of the CP-loop– is visible in one of 
the six subunits and points towards the active site but does not interact with CP. The 
repositioning of CP-loop is further stabilized by hydrogen bonds between the carbonyl O of 
T1998 and the N of S2000, both in the CP-loop, with the N atom of S1973 and the side chain 
of T1974 in the adjacent subunit.  
 
Figure 23. huATCase subunit and ligand-induced conformational movements. Cartoon 
representation of huATCase subunit free of ligands (A), bound to CP (B) or in complex with PALA (C). 
Ligands are shown in spheres and disordered regions are indicated in dashed trace. Secondary 
elements are labelled in (A) and coloured as in Fig. 22. Rotation axes for hinge-closure of the C-
domain and for Asp-loop movement are indicated with black lines and curved arrows. (D-F) Ca trace 
superposition of the six subunits within the asymmetric unit. The root-mean-square-deviation (RMSD) 
for the position of the superposed Ca atoms is indicated. 
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 In addition to the re-positioning of the CP-loop, the binding of CP results in an overall 
closure of the active site cleft, consisting on a 5º rotation of the C-domain around a hinge 
located at residues D2059 (helix H5) and A2207 (helix H12) in the two helices 
interconnecting the N- and C-domains (Figure 23B). Overall, the CP-induced movements 
alter the shape of the active site and drag the side chains of K2003 and R2146 towards a 
contiguous pocket adjacent to the CP site, which becomes primed for the binding of Asp.  
 
10. PALA glues the N- and C-domains in a closed conformation 
 The simultaneous occupation of the CP and Asp binding sites by the molecule of 
PALA induces a more pronounced closure of the huATCase subunit compared to the CP-
bound state (Figure 23C and 24B). The C-domain undergoes a rotation of 9º around the 
same hinge-axis described before, located at the helices interconnecting the N- and C-
domains. In addition, compared to the observed position in subunit F in the huATCase-apo 
structure, the binding of PALA triggers a 28º rotation 
of the Aps-loop around a hinge located at residues 
2145- 2147 and 2166- 2167 (Figure 23C). The Asp-
loop harbours a conserved RxQxER sequence that 
confers specificity for Asp (Yuan et al., 1996). In this 
rigid body rotation, these residues undergo a ~10 Å 
displacement in order to interact with the inhibitor 
molecule (Figure 23B). The protein completely 
surrounds the molecule of PALA, excluding it from the 
solution, and interacts with every polar atom of the 
inhibitor (Figure 24B,C). The phosphonate group of 
PALA occupies the position of the phosphate group of 
CP, and interacts with the side chains of residues 
S1973, R1975, T1976 and R2024 and with the N 
atoms of R1975 and T1976 (Figure 24B). 
 
Figure 24. huATCase active site. (A) Active site of 
huATCase bound to CP. Ligands are colored with C atoms 
in magenta and residues are colored with C atoms in blue 
(N-domain), green (C-domain), orange (Asp-loop) or yellow 
(CP-loop from adjacent subunit). The electron density map 
for CP is shown. (B) Superimposition of PALA-bound active 
sites of huATCase and ecATCase-C3. huATCase is 
colored as in (B) and E. coli C atoms are colored in grey. 
(C) Surface representation of the huATCase subunit 
(colored in blue) with the repositioning of the CP-loop from 
the adjacent subunit (colored in brown). A molecule of 
PALA bound within the active site is shown as spheres. 
The surface is represented semitransparent and some of 
the protein elements are shown in ball-and-stick.  
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 At the C-domain, the b-carboxylate of PALA interacts with the side chains of R2146 
and Q2148 (in the Asp-loop), whereas the a-carboxylate complements the positive side 
chain of R2085. The carbonyl O of PALA is at hydrogen bond distance from the side chains 
of T1976, R2024 and H2052, and the N atom interacts with the carbonyl O of M2185. 
Moreover, the CP-loop from the adjacent subunit occupies the position observed in the 
huATCase-CP crystal and interacts with the phosphonate group of PALA through the side 
chain of S2000. The side chain of K2003 is well-defined in the huATCase-PALA structure 
and occupies a central position within the active site, with the side chain amino group at 
hydrogen bond distance from the a- and b-carboxylates, the N-atom and the phosphonate 
group of PALA.  
 Altogether, the interactions with PALA, which are summarized in Table 7, glue the N- 
and C-domains into a closed state further stabilized by a salt bridge between the side chains 
of R2151 (Asp-loop) and E1971 (loop preceding helix H2), by hydrogen bonding between 
R2151 (Asp-loop) and P2026 (loop S4-H4), and by extensive Van der Waals contacts 
between the Asp-loop and the CP-loop from the neighbour subunit.  
 
Table 5. Interactions with PALA in the active site of huATCase. Asterisks show the residues from the 
adjacent subunit. 
Residue Residue 
atom 
PALA atom Distance A 
(Å) 
Distance B 
(Å) 
Distance C 
(Å) 
S1973 OG O3P 2.69 2.53 2.65 
T1954 N O2P 2.86 3.01 3.08 
R1975 N O2P 2.84 3.02 2.91 
 NE O2P 3.13 3.03 3.18 
 NH2 O2P 3.15 2.89 2.57 
T1976 N O3P 2.87 3.03 2.73 
 OG1 O1 3.18 3.24 3.18 
 OG1 O3P 2.48 2.68 2.77 
R2024 NH1 O1P 2.71 2.86 3.04 
 NH2 O1 3.13 2.85 2.86 
R2024 NH1 O3P 3.30 3.18 3.77 
H2052 NE2 O1 3.16 2.91 3.30 
R2085 NE O2 2.91 2.55 2.75 
 NE O3 3.53 3.22 3.71 
 NH2 O3 3.21 3.22 2.72 
 NH2 O2 4.03 - 3.18 
R2146 NE O4 2.78 3.41 2.92 
 NH2 O5 3.23 3.34 3.12 
 NH2 O4 3.25 3.64 3.38 
Q2148 NE2 O4 3.39 2.68 2.61 
M2185 O N2 3.02 3.01 2.77 
S2000* OG O2P 2.95 3.10 2.94 
 OG O1P 3.28 3.04 3.24 
K2003* NZ O5 3.11 2.80 2.95 
 NZ O3 2.88 2.98 2.65 
 NZ O1P 2.67 2.95 2.43 
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 The PALA-induced motions are also coupled to a global change in the relative 
position of the subunits within the trimer (Figure 25). Looking at the huATCase trimer from 
the bottom face, the transition from the apo- to the PALA-state can be described as a 5º 
clock-wise rotation of the C-domains, with a 0.5–1 Å movement of the subunits towards the 
threefold axis. In a lateral view, the subunits come nearer at the bottom entrance of the 
central tunnel and separate by 1-2 Å at the top entrance delimited by the loops H1-S2. Upon 
PALA binding, there is also a displacement of 0.5-1 Å of helix H2 and strand S3, the two 
elements shaping the central tunnel, along the threefold axis and away from the active site 
(Figure 26). 
 
 
 
 
 
 
 
Figure 25. Conformational changes in huATCase induced by PALA. Stereoview of the 
superposition between huATCase trimer free (grey) and bound to PALA (red). 
 
 
   
 
 
human ATCase
apo-form / PALA-bound
90º
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Figure 26. Ligand-induced conformational changes near the central tunnel. Cartoon 
representation of the superposition of huATCase free and bound to PALA, showing only the 
secondary elements shaping the central tunnel in perpendicular view to the threefold axis. The apo 
structure is shown in lighter colour tones. PALA and glycerol are represented as spheres. The arrows 
indicate the movement of helix H2 and strand S3 upon binding of PALA. 
 
11. Comparison with E. coli ATCase reveals unique structural features in the ATCase 
domain of CAD 
 The huATCase structures confirm the predicted overall similarity with the catalytic 
trimers of ecATCase (Scully and Evans, 1991). Both proteins share a 44% sequence identity 
and the topology and length of the secondary elements are alike (Figure 27).  
 The subunits of human and E. coli ATCase free of ligands superimpose with an 
RMSD of 1.45 Å for 270 compared Ca's, whereas superposition of the PALA-bound 
conformations yield a RMSD of 1.06 Å for 296 Ca's (Figure 28). The two proteins are even 
more alike at the active sites (Figure 24B). The residues and interactions with CP or PALA 
are fully conserved with the exception of L267 in ecATCase-C3 that is replaced by M2185 in 
human CAD (Figures 24B and 27). This residue contributes to the active site through the 
carbonyl oxygen and thus, the interactions with the ligands are the same in both proteins. In 
addition, the orientations of residues R1975 and H2052 are slightly different in the E. coli 
enzyme, but this could result from differences in the refinement of the models. Overall, the 
striking similarity between the two proteins and the virtually identical active sites strongly 
support that the catalytic mechanism proposed for ecATCase will fully apply to CAD.  
 Therefore, we asked what structural features could be responsible for the unique 
cooperative kinetic properties found in the human enzyme. The N- and C-termini of 
huATCase are four residues longer and three residues shorter, respectively, compared to 
ecATCase. Structural-guided sequence alignment with E. coli ATCase also revealed that 
huATCase presents two insertions and four deletions (Figure 27, highlighted in reddish). 
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Figure 27. Sequence alignment of huATCase and E. coli ATCase catalytic subunit. Residues are 
coloured according to the secondary structure, which is drawn above the sequence. a-helices and b-
strands are represented as cylinders and arrows, respectively. Residues interacting with PALA are 
shown in yellow background. The different insertions and deletions between the two sequences are 
highlighted with reddish rectangles. 
   
Out of these, the most notable difference compared to ecATCase is the four-residue insertion 
at the C-end of helix H1 in huATCase. These residues fold as an additional turn at the C-end 
of helix H1 on the top face of the trimer (Figures 28 and 29). This helix is not only longer in 
huATCase, but it is also displaced 2-3 Å along its axis towards the adjacent subunit and tilted 
7º towards the threefold axis compared to ecATCase. As a result, the loop H1-S2 is placed 8 
Å closer to the center of the molecule and participates extensively in intersubunit contacts 
(Figures 29A). The first residue in the loop, E1954, which is invariant in CAD sequences but 
absent in bacterial ATCases, interacts with the side chains of residues R2224 and K1963 in 
the adjacent subunit. The loop residues D1958 and K1961 also interact with the same 
residues in the other subunits, forming a network of ion-pairs at the top entrance of the 
central tunnel (Figures 29B). These two residues are conserved in ecATCase (E37 and K40) 
but, based on the crystals structures, do not participate in intersubunit contacts (Figures 
29B).  
 Another significant difference with ecATCase is the two-residue deletion in the human 
CP-loop (Figures 27). As already mentioned, in the absence of ligands, this loop in 
huATCase is disordered (Figure 23A). In contrast, in ecATCase, this loop forms important 
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intersubunit interactions that involved residues D75 and N78 from different subunits even in 
absence of ligands (Figures 28 and 29). The interactions between E. coli subunits are 
reinforced by hydrogen bonding of R56 (helix H2) and G72 (strand S3). Thus, whereas in the 
absence of ligands ecATCase subunits are interrelated mainly through the interactions near 
the bottom entrance of the central tunnel, the huATCase trimer is hooked together through a 
network of ion-pairs on the top entrance of the tunnel, whereas the intersubunit contacts near 
the active sites are loose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Structural comparison of huATCase subunit and ecATCase catalytic chain. 
Stereoview of the superposition of huATCase (in red) and ecATCase catalytic chain (in grey) free of 
substrates (A) or bound to PALA (B). The subunits are shown in Ca trace and PALA molecules in ball-
and-stick representation.  
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CP-loop
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PALA-bound
RMSD = 1.45 Å
for 270 Cα atoms
RMSD = 1.06 Å
for 296 Cα atoms
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 Upon PALA binding, the trimer shows a more compact conformation than ecATCase 
(Figures 25 and 28). The C-domains of huATCase are 1- 2 Å closer towards the adjacent 
subunits and helix H2, strand S3 and the CP-loop are 1-2 Å nearer the threefold axis. The 
smaller size of the residues in helix H2 facing the central tunnel, the shorter CP-loop and the 
lack of interactions at the bottom entrance of the tunnel may facilitate the approximation 
between the huATCase subunits (Figure 29C).   
 
Figure 29. huATCase intersubunit contacts. (A) Superposition of huATCase trimer (purple) and 
ecATCase-C3 (magenta) bound to PALA in two perpendicular views. Left, view along the threefold 
axis from the top face, with helix H1 and loop H1-S2 highlighted in a darker color. Right, lateral view 
with the front subunit removed and the two other two subunits colored in different tone. (B, C) Zoomed 
views showing the intersubunit contacts for huATCase (top) and ecATCase-C3 (bottom). 
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12. Loop H1-S2 interactions are key for huATCase stability and functioning 
12.1. Purification of the H1-S2 mutants and determination of the oligomeric state 
 To test the significance of the loop H1-S2 interactions, we mutated residues E1954 
and D1958 to alanine. Both mutants, huATCase-E1954A and huATCase-D1958A, were 
expressed and purified following the same protocol as for the wild-type protein (huATCase-
WT), but the yield of huATCase-E1954A was 5-fold lower (Figure 30A).  
 We noticed that whereas in the final gel-filtration step the mutant D1958A eluted as a 
single peak similarly to huATCase-WT, the elution peak for huATCase-E1954A was double 
(Figure 30B). Based on the calibration of the size exclusion column with standards of known 
molecular weight, we estimated that this second peak could correspond to partially 
dissociated monomers or dimers of the protein.  
 SEC-MALS analysis further corroborated that similarly to the wild-type, the mutant 
D1958A forms trimers in solution at concentrations above 0.15 mg ml-1, whereas the 
mutation E1954A causes a partial dissociation of the oligomers at similar concentrations 
(Figure 30C,D). We pooled the fractions corresponding to the trimer and re-injected the 
sample in the size-exclusion chromatography, this time at a concentration below 0.3 mg ml-1. 
The elution profile of the second injection demonstrated that, at these concentrations, the 
oligomer is in association-dissociation equilibrium since a second elution peak was evident. 
The molecular mass measurement of this second elution peak was imprecise and did not 
allow us to discern if the species corresponds to a monomer, a dimer or a mixture of both.  
 Sedimentation velocity experiments showed two species (Figure 30E,F), one 
corresponding to the trimer and a second species with a sedimentation coefficient of 4.8 S 
and an estimated molecular mass of 40 kDa that matched the expected size of the monomer. 
The estimated dissociation constant of the E1954A and D1958A mutants is 4.5-fold and 2.7-
fold higher than huATCase-WT, respectively. These results prove that the interactions at the 
top face of the trimer, absent in ecATCase, are key for the oligomerization of huATCase 
subunits. 
 
12.2. Thermal stability 
 The mutations in the H1-S2 loop did not have a significant effect on the thermal 
stability of the protein. Thermal shift assays showed that, compared to wild-type (Figure 13), 
the mutations E1954A and D1958A do not significantly affect the TM of the protein in the 
absence of ligands (TME1954A,apo = 48 ºC; TMD1958A,apo = 51 ºC) (Figure 31A,B). Adding CP or 
PALA increased the TM of both mutants to approximately 65 ºC and 76 ºC, respectively, 
which are lower values than those measured for the wild-type. 
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Figure 30. The loop H1-S2 mutants destabilize the trimer. (A) Purification of mutant E1954A 
monitored by SDS-PAGE. L, cell lysate; S, supernatant; FNi, WNi and ENi, flowthrough, wash and 
elution from Ni-affinity column; D, dialyzed and digested with PreScission; FS and ES, flowthrough and 
elution from S column. (B) Semilogaritmic plot of the molecular mass versus the elution volume from a 
Superdex 75 column. The circles indicate the elution volume of proteins standards (in black; 1, 
thyroglobulin; 2, ferritin; 3, aldolase; 4, conalbumin; 5, ovalbumin) and of the E1954A (red) and 
D1958A (green) mutants. (C, D) SEC-MALS analysis. The differential refractive index and the molar 
mass are shown in black and red trace, respectively. In grey, peak fractions re-injected. (E) 
Sedimentation velocity assays and (F) estimation of the dissociation constants (KD) for the mutants. 
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Figure 31. Stability, activity and ligand binding of the loop H1-S2 mutants. (A,B) Denaturing 
curves of E1954A (A) and D1958A (B) mutants measured in buffer Tris-acetate pH 8.3 in the absence 
or in the presence of ligands. (C,D) Substrate saturation curves at 10 mM Asp (C) or 5 mM CP (D) and 
varying the concentration of the other substrate. The kinetic parameters for mutant D1958A are Vapp= 
1.72 mmoles h-1 mg-1, [CP]0.5 = 0.11 mM, [Asp]0.5app = 0.57 mM and nH = 1.7- 2.4, whereas mutant 
E1954A shows Vapp= 0.99 mmoles h-1 mg-1, [CP]0.5app = 0.13 mM, [Asp]0.5app = 1.66 mM and nH = 1.9. 
(E) Calorimetric titrations for the interaction of the mutants with CP (left) or PALA (right). The upper 
plots show the thermogram (thermal power as a function of time) and lower plots show the binding 
isotherm (normalized heat per injection as a function of the molar ratio ligand:protein). 
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12.3. Effects on enzyme activity and ligand binding 
 The loop H1-S2 mutations also altered the kinetic and the binding parameters of 
huATCase. Mutations D1958A and E1954A reduce the activity 2.5-fold and 4-fold, 
respectively (Figure 31C,D), likely due to the impaired protein oligomerization at the 
concentrations of enzyme used during the assays.  
 ITC experiments performed at protein concentrations (40 µM) at which both mutants 
form mostly trimers (Figure 30F) proved the binding of three CP molecules with similar 
affinities to wild-type (Figure 31E). However, the affinity and cooperativity for the binding of 
PALA are clearly affected. Both mutants exhibit similar dissociation constants for the first and 
second binding sites for PALA (KD1= KD2 ≈ 1 µM), which mean a ~50-fold lower affinity than 
the wild-type. Then, whereas D1958A mutant exhibits signs of negative cooperativity with a 
3-fold decrease in affinity for the third site (KD3= 3.2 µM), the E1954A mutant shows 
increased affinity of the third site (KD3= 0.1 µM). These results demonstrate that disruption of 
the contacts through the loop H1-S2 somehow impacts on the activity and on the 
cooperativity between the active sites.  
 
13. In vitro characterization of mutation R2024Q 
 The mutation R2024Q was recently described as the cause of the first case of a 
partial deficit of human CAD (Ng et al., 2015). The present structures show that R2024, 
similarly to the equivalent residues in ecATCase (R105) and in B. subtilis ATCase (R99), is a 
central element of the active site that directly interacts with CP (Figure 24A). Intriguingly, 
mutations of this arginine to alanine in the isolated catalytic ATCase trimer of E. coli 
(ecATCase-C3; mutation R105A) and in B. subtillis ATCase (R99A) were reported to confer 
positive cooperativity for Asp and to severely decrease the activity and the affinity for the 
substrates (Stebbins and Kantrowitz, 1992, Stebbins et al., 1989). To better understand the 
effect of this arginine and the effect of the R2024Q substitution in CAD, we produced and 
characterized the mutant huATCase-R2024Q.  
 The R2024Q mutant was expressed as the wild-type and the purification required 
small changes due to the reduced solubility of the protein at low salt concentrations (Figure 
32A). The mutations does not affect the oligomeric state of the protein, as was demonstrated 
by SEC-MALS analysis (Figure 32B). The stability of the mutant in absence of ligands was 
also similar to wild-type (Figure 32C), indicating that the mutation does not affect protein 
folding. The increment in TM upon addition of CP or PALA was 10 ºC lower compared with 
the wild-type and suggested a markedly reduced affinity for the ligands (Figure 32C,D). 
Indeed, ITC experiments proved that the affinity for CP was 7-fold lower than in the wild-type 
(KDCP = 42 µM), and we could only detect binding of PALA to one site per trimer and with 
very low affinity (KD = 120 µM) (Figure 32E). 
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Figure 32. Characterization of R2024Q mutant. (A) Purification of huATCase-R2024Q monitored by 
SDS-PAGE. Fractions of the second Ni2+-column indicate the elution at different concentrations of 
imidazole, with R2024Q eluting at 40 mM. (B) SEC-MALS analysis shows the formation of a stable 
R2024Q trimer. (C) Denaturing curves in the absence and presence of ligands. (D) Graphical 
comparison of the increment of TM at varying concentrations of ligand for mutant R2024Q and for wild-
type (inset). (E) CP and PALA binding to R2024Q mutant measured by ITC. (F) Substrate saturation 
curves at fix concentrations of Asp (10 mM, left panel) or CP (5mM, right panel). Inset, increased 
sigmoidictiy of the curve at low Asp concentration. Fitting to Michaelis-Menten or Hill equations are 
shown as grey dashed line or black lines, respectively. 
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 The mutation virtually inactivates the enzyme, reducing the activity ~1000-fold (Figure 
32F). The residual activity of R2024Q shows increased sigmoidicity, with a nH = 2.7, a value 
that is similar to the ecATCase holoenzyme (nH =2.6, (Mendes and Kantrowitz)), and also a 
more pronounced inhibition by Asp than the wild-type or the loop H1-S2 mutants (Figure 32F, 
right panel). 
 
14. Isolation, mutagenesis and preliminary characterization of the bifunctional human 
DHOase–ATCase construct 
14.1. Recombinant human DHOase-ATCase forms homohexamers in solution 
 It has been previously proposed that the 1.5 MDa CAD particle assembles by 
association of three polypeptide chains through their ATCase domains into a trimer, and then 
two of these trimers can further dimerize by interactions of the DHOase domains (Evans, 
1986, Irvine et al., Carrey, 1995). Thus, CAD hexamer would result from a "dimer of trimers", 
with DHOase and ATCase playing a central scaffolding role in the structure of the particles. 
To test this hypothesis, we cloned a bifunctional construct encoding the human DHOase and 
ATCase domain (from M1456 to F2225; nucleotides 4365–6704). This construct also 
includes the 91 amino acid sequence linking both domains. This linker is rich in residues of 
proline (22%) and contains the residue S1859 that is phosphorylated by S6 kinase and PKA 
(Ben-Sahra et al., 2013, Robitaille et al., 2013, Carrey et al., 1985). The huDHOaseATCase 
construct was cloned into the pOPIN-F vector to introduce a cleavable N-terminal 
polyhistidine tag. The protein was expressed in human HEK293 cells (data not shown). This 
time, the addition of MBP was not required for protein solubility. Indeed, the presence of an 
MBP-tag at the N-terminus of the construct decreased the expression level (data now 
shown). Apparently, the presence of the DHOase domain is sufficient to allow the expression 
of the ATCase. 
 huDHOaseATCase was purified using three chromatographic steps: Ni2+-affinity 
column followed by PreScission digestion of the His-tag, a second Ni2+-affinity column and a 
size-exclusion chromatography (Figure 33). The purification yields ~3 mg of pure 
huDHOaseATCase per litre of HEK293 culture. The purified huDHOaseATCase migrated on 
a SDS-PAGE at the expected molecular weight of 84.70 KDa. The protein elutes from the 
size-exclusion chromatography as a major single peak at approximately 10 ml (Figure 32F), 
which corresponds to a complex of 560 KDa, in good agreement with the formation of a 
homo-hexamer in solution (theoretical molecular mass 508.1 kDa). A small shoulder in the 
void volume of the column indicates the presence of some aggregated material. A second 
shoulder at 12 ml also suggests partial dissociation into smaller oligomers. The analysis of 
the elution fractions by SDS-PAGE showed that the protein is highly pure and that all 
fractions in the main and secondary peaks correspond to the huDHOaseATCase (Figure 
33E,F). The molecular mass of the oligomer was accurately measured by SEC-MALS using 
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a Superose 6 column. The protein eluted as a single peak with an average molecular mass of 
469 kDa (± 0.15%) (Figure 34). However, the MALS measurement indicated that the sample 
was polydisperse.  
 
 
 
 
Figure 33. huDHOaseATCase purification. (A,B) Chromatogram and SDS-PAGE of Ni-affinity 
column. The blue line shows the elution profile monitored by UV absorption at 280 nm. L, cell lysate; 
S, clarified supernatant; F, flow through; W, wash with 60 mM imidazole; E, elution in 250 mM 
imidazole. (C,D) Following dialysis and digestion with PreScission (DD), the sample was loaded on a 
second Ni-affinity column. huDHOaseATCase does not bind the column (Ft) while the non-cleaved 
protein and contaminants remain attached to the column (E1 and E2). (E,F) Chromatogram of size-
exclusion column (Superdex 200) and SDS-PAGE of the peak fractions. 
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14.2. Site-directed mutagenesis demonstrates the existence of a "dimer of trimers" 
 We introduced in the huDHOaseATCase construct mutations that are reported to 
prevent the oligomerization of the DHOase and ATCase domains. On the one hand, mutation 
M1601E was proved in our group to disrupt the dimerization of the isolated DHOase domain 
of human CAD (Grande-García et al., 2014). 
On the other hand, the mutation D2009A led 
to the dissociation of the isolated hamster 
ATCase trimers (Qiu and Davidson, 1998), 
mimicking the effect of the mutation D90 in 
ecATCase. In the context of full-length 
protein, the mutation D2009A was also shown 
to prevent the formation of hexamers (Qiu and 
Davidson, 2000). Both, the M1601E and 
D2009A huDHOaseATCase mutants were 
expressed and purified as the wild-type 
protein, although the recovery was 
approximately half than for the wild-type (1- 2 
mg of pure protein per litre of HEK293 cells). 
Analysis by SEC-MALS demonstrated that the 
M1601E mutant eluted in a major peak with 
an average molecular weight of 271 kDa (± 
0.33%), in good agreement with the formation 
of a trimer (theoretical mass 254.1 kDa) 
(Figure 34B). On the other hand, mutant 
D2009A eluted in a single peak with an 
average molecular weight of 182 kDa (± 
0.50%), indicating the formation of a dimer in 
solution (theoretical mass 169.4 kDa) (Figure 
34B).  
 We also mutated Ser1859 to 
glutamate or to aspartate to mimic the 
phosphorylation of this residue by the 
mTORC1 signalling pathway. It was reported 
that the phosphorylation of this residue 
promoted CAD oligomerization, a conclusion 
that was based on the formation of 
fluorescent foci and in changes in the 
sedimentation of the protein in centrifugation 
Figure 34. Determination of the oligomeric 
state of huDHOaseATCase. (A) SEC-MALS 
measurements of huDHOaseATCase-WT. (B) 
Superposition of the SEC-MALS measurements 
of huDHOaseATCase WT (black) and the 
mutants M1606E (blue) and D2009A (red). 
SEC-MALS analysis demonstrates that the 
oligomeric state is disrupted by the mutations. 
(C) Superposition of the measurements for WT 
(black), S1859D (green) and S1859E (purple).  
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gradients (Ben-Sahra et al., 2013, Robitaille et al., 2013). Once again, huDHOaseATCase 
mutants S1895E and S1895D were expressed and purified as wild-type. This time, we did 
not notice differences in the yield during purification compared with the wild-type. The 
analysis by SEC-MALS demonstrated that both mutants form homohexamers in solution with 
an average molecular weight of 271 kDa (± 0.1%). The mutant S1859D appeared to have 
more aggregated material than the wild-type. Contrary, the mutant S1859E eluted in a 
narrower and more symmetric peak than wild-type, suggesting a more compact and less 
polydisperse hexamer (Figure 34C). 
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1. First time production of the ATCase domain of human CAD 
 ATCase is the smallest of the four functional domains of CAD, but its role is central 
for the assembly of the 1.5 MDa hexameric particles. Pioneering work from J. Davidson's 
group demonstrated that a single-point mutation in the ATCase domain is sufficient to disrupt 
the oligomerization of hamster CAD (Qiu and Davidson, 2000). This result strengthened the 
assumption that CAD hexamers are formed by the dimerization of ATCase-mediated CAD 
trimers (Irvine et al., 1997). To get insight into the architecture of CAD, we aimed to isolate 
the ATCase domain for detailed structural characterization. 
 We succeeded in producing for the first time the recombinant ATCase domain of 
human CAD using both bacteria and human cells as heterologous expression systems. In 
the group, we routinely test the addition of different fusion partners or tags to the targeted 
proteins to improve their expression, solubility and purification. The ATCase domain of CAD 
is a clear example of the benefits of this strategy. We fused the N-terminus of huATCase to a 
hexahistine (His6)-tag or to a dual His6-maltose-binding protein (MBP) tag, but only the latter 
was efficiently expressed (Figure 10). These results were in agreement with a previous study 
from the group of Davidson reporting that the ATCase of hamster CAD was expressed 
soluble when fused to MBP (Qiu and Davidson, 1998). The precise mechanism by which 
MBP allows the expression of this domain of CAD has not been investigated. E. coli MBP is 
a large (43 kDa) stable and highly soluble protein, ranked as one of the best tags for 
enhancing the production and folding of passenger proteins (Kapust and Waugh, 1999, Fox 
et al., 2001, Costa et al., 2014). MBP has been reported to attract GroEL and to drive the 
tagged proteins into favourable chaperone environments for correct folding (Douette et al., 
2005). Additionally, MBP presents a hydrophobic binding cleft, adjustable to accommodate 
different polypeptides, which can interact with the passenger protein (Kapust and Waugh, 
1999, Fox et al., 2001). It is plausible that this intrinsic affinity endows MBP with a 
chaperone-like activity that assists in the folding of ATCase subunits by protecting exposed 
hydrophobic patches prior to their oligomerization.  
 The work of Davidson also demonstrated that the MBP-tag does not interfere with the 
activity of hamster ATCase (Qiu and Davidson, 1998). However, they did not test if the 
protein was stable upon removal of the MBP. We wanted to remove the MBP for 
crystallization purposes, and thus, a PreScission protease site was included in the protein 
construct to cleave off the tag. We proved that huATCase is soluble and stable in absence of 
the carrier protein, suggesting that MBP is only required for initial translation and folding. 
Unfortunately, all the advantages as a solubility enhancer turn into a curse when it comes to 
the purification of huATCase from the cleaved MBP, which becomes a major contaminant in 
the preparations. Additional chromatographic steps, such as a second Ni2+-column, or 
amylose resins, proved to be inefficient for the binding of His6-MBP. These difficulties made 
us suspect that, at high salt conditions favouring hydrophobic interactions, huATCase might 
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bind to the cleaved MBP reducing its affinity for the resins, as it has been described for other 
proteins (Fox et al., 2001). Luckily, at physiological salt concentrations, the separation of the 
two proteins is feasible using anion exchange chromatography. The huATCase sample freed 
from MBP showed only one other persistent but minor contaminant, identified as E. coli CAP 
protein.  
 We corroborated by SEC-MALS and AUC analysis that, similarly to other members of 
the transcarbamoylase family, huATCase forms trimers in solution (Figure 12 and 13). 
Although it is not the focus of this thesis, it is important to highlight that the observation that 
huATCase easily dissociates at concentrations ~0.01 mg/ml (KD = 0.27 µM) has led us to re-
design ongoing experiments aiming at visualizing full-length CAD by electron microscopy 
(EM). The preparation of grids for EM requires diluted samples at which we now know that 
favour the dissociation of the ATCase trimer. Now, dissociation of the CAD particles is 
prevented by chemical cross-linking which notably increases the homogeneity of the EM 
samples.  
 
2. A picky protein leads to troublesome crystals 
 The first crystals of huATCase appeared in few hours, but four years later, the 
optimization of the crystallization conditions is still a pending matter. We do not understand 
yet how to control the conditions that lid from small thin and poorly diffracting plates to the 
growth of few thicker and well diffracting crystals. The other only factor that was found to 
make a difference in crystallization trials is protein freshness. Using the protein straight from 
the purification, without freezing or storage, was decisive to palliate excessive crystal 
nucleation, although it did not grant the reproducible growth of sizeable single crystals. 
Protein freezing was not only detrimental for crystallization but also caused partial protein 
precipitation and loss of activity. By assessing different freezing conditions, we concluded 
that the activity of the samples with no cryo-protectant or supplemented with 40% glycerol, 
decayed to 50% after three-weeks storage at -80 ºC. After thawing, part of the protein 
precipitated and the soluble fraction exhibited a decreased in VMapp but similar S0.5 values as 
the non-frozen samples, suggesting that part of the soluble protein was somehow damaged. 
The use of a 30% DMSO/ 5% glycerol had been reported in the past for the preservation of 
CAD (Coleman et al., 1977). This DMSO/glycerol mix did not prevent the precipitation of ~20 
% of the protein after thawing, but conserved the specific activity of the soluble fraction. We 
suspect that although the sample is extensively centrifuged and filtered, the presence of a 
small fraction of precipitated or aggregated material could be the cause of excessive 
nucleation in the crystallization trials. 
 Since the refinement of crystallization conditions appeared fruitless, a brute-force 
screening of crystals was needed to find those of sufficient quality to collect complete 
datasets. In principle, the diffraction patterns were successfully indexed by invoking a single 
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lattice. The data was indexed and scaled in a primitive hexagonal lattice and space group 
P6322. This indicated the presence of one huATCase subunit per asymmetric unit making a 
perfectly symmetric trimer in the crystal lattice. We did not notice any problem, except for the 
statistical distribution of intensities that deviated from what is expected for a reasonably 
untwinned data. Since this spacegroup admits no (pseudo)merohedral twin laws, it pointed to 
overmerging of pseudo-symmetric data or bad data quality. The molecular replacement with 
one E. coli ATCase catalytic subunit found a correct solution, but the model building and 
refinement was stalled at high values of R and Rfree. Then, we re-scaled the data in lower 
symmetry space groups observing a marginal improvement of the statistics (Tables 4 and 5). 
The symmetry was eventually lowered to P21, and the refinement of two huATCase trimers 
per asymmetric unit led to acceptable R and Rfree values. The crystal presents a 
"pseudosymmetry" problem, the molecular 3-fold axis is close to a true crystallographic 
symmetry, but the subunits within the molecule are indeed sufficiently different from each 
other. The non-crystallographic symmetry and the twinning operators combine to create an 
apparent 622 point symmetry. This problem was difficult to detect and could only be 
confirmed at a late stage during the refinement of the model. Luckily, twinning is not a fatal 
disease for non-expert crystallographers anymore and REFMAC5 is capable of working with 
multiple twinning operators, and to estimate and refine the twin fractions of the crystal 
between cycles of structural refinement (Murshudov et al., 2011), allowing us to determine 
the structure of huATCase.  
 
3. Three snapshots along huATCase catalytic cycle 
 The unprecedented atomic view of the ATCase domain of CAD confirms the 
conservation of the overall fold and the virtually identical active site with bacterial 
homologues (Figures 24B and 28). The differences between the three huATCase structures, 
free of ligands, bound to CP and in complex with PALA, also indicate that similarly to other 
transcarbamoylases (Shi et al., 2015), the ATCase domain of CAD must undergo large 
conformational changes to complete the catalytic cycle (Figure 23).  
 In absence of ligands, huATCase shows an open fold with the CP- and Asp- loops 
flexibly disordered (Figure 22 and 23). The overall conformation resembles the ecATC-C3 
free of ligands but with fewer intersubunit contacts near the active sites. Then, as described 
for other ATCases, CP binds in first place and with high affinity to three independent and 
equivalent binding sites, causing a significant increase in protein stability by induced-
positioning of the CP-loop over the active site of an adjacent subunit. The addition of Asp in 
absence of CP results in a negligible increase of protein stability, suggesting that there is no 
binding at the active site, or that the ligands do not trigger the conformational changes 
observed in the structures with CP (Figure 14). The positioning of the CP-loop fastens the 
loose intersubunit contacts at the bottom face of the trimer and together with partial approach 
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of the C-domain prepares the site for Asp. Binding of Asp must be concomitant with the 
closure of the active site to a conformation similar to the PALA-state, where the N- and C-
domains compress the substrates in the correct orientations to react (Lipscomb and 
Kantrowitz, 2012). The closed huATCase-PALA structure shows three molecules of PALA 
engulfed by hinge-closure of their respective subunits and by rearrangement of the CP- and 
Asp-loops. Thermal shift assays have proven that this conformation is highly stable and 
cannot be mimic by the addition of CP and the inert Asp analogue succinate (Figure 14). 
Thus, the 10º hinge-closure of the C-domain and the ~30º rotation of the Asp-loop respond to 
a highly specific recognition of the ligand bound in the active site. Dissociation of PALA from 
this highly stable complex is impossible without reversing the conformational changes.  
 In the inhibition assays, where the enzyme is pre-incubated with PALA, we observed 
a substantial lag in catalytic activity before the linear formation of CAsp (Figure 18D). This 
lag is interpreted as a slow opening of the hinge and CP- and Asp-loops required for release 
of PALA and subsequent access by the CP and Asp. Indeed, the analysis of the kinetics of 
the interaction of PALA with ecATC-C3, led to a mechanism involving a rapid binding of the 
bisubstrate ligand followed by a much slower isomerization of the complex (Cohen and 
Schachman, 1986). A similar behavior in huATCase, with a slow dissociation of PALA 
compared to substrate binding or catalytic turnover, would explain the behavior of PALA as a 
nearly irreversible inhibitor (Figure 18E). 
 
4. Homotropic cooperativity in huATCase 
 Whereas the structural studies only provided unexciting similarities between 
huATCase and bacterial homologues, the characterization of kinetic and binding parameters 
pointed in a completely different and surprising direction.  
 The substrate saturation curves measured for huATCase did not obey Michaelis-
Menten equation and formed slightly sigmoid curves, suggesting that the enzyme displays 
cooperativity between the active sites in the trimer (Figure 16). These results were quite 
puzzling since isolated bacterial ATCase trimers that shared strong structural similarity with 
the human enzyme were clearly reported as non-cooperative, a property that was reserved 
for the ecATCase holoenzyme (Porter et al., 1969, Gerhart and Holoubek, 1967). However, 
cooperativity was not the only plausible explanation for the sigmoidal kinetic behaviour. 
Activity is measured at protein concentrations (0.04 µM) 5-fold lower than KD for the trimer, 
and although the dilution buffers contain 0.1 mg ml-1 BSA and this could have a crowding 
effect that favours oligomerization, it is possible that in the assay a fraction of the enzyme is 
in the inactive monomeric state. On the other hand, it is reported that CP –and PALA– 
promotes the association of ATCase trimers (Qiu and Davidson, 2000). Thus, the deviation 
of the Michaelis-Menten equation with abnormally reduced rates at low substrate 
concentrations could be related to the dissociation of the trimers. Nevertheless, the abrupt 
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flattening of the initial rates at higher substrate concentrations was another indication of a 
sigmoid and different from the rectangular hyperbola defined by the Michaelis-Menten 
equation.  
 We were only convinced of the cooperation between huATCase subunits by 
analysing the binding of PALA. The accurate measurement of different affinities for PALA in 
the three active sites of the trimer demonstrated without doubt the existence of homotropic 
cooperativity in the huATCase domain. Homotropic cooperativity arises when ligand-binding 
affinity of one active site is affected by the same ligand bound to a neighbour active site 
(Perutz, 1989). The evidence of such phenomenon in huATCase was clear, but a 
mechanistic explanation is troublesome since cooperativity shows a double face. On the one 
hand, binding of PALA decreases the affinity for the inhibitor at the vacant sites (negative 
cooperativity) but on the other hand, binding of substrates has the opposite effect and 
increases the affinity in the unliganded subunits (positive cooperativity).  
 Based on the structural data, we proposed a model to explain the complex kinetic 
behavior of huATCase (Figure 35). This model presupposes a progressive transformation of 
the trimer from an open to a closed state, where the crystal structures of huATCase free or 
bound to CP and in complex with PALA illustrate few of the possible conformations, with all 
the subunits in a similar state. Assuming the existence of intermediate states for which we do 
not have structural information, the negative cooperativity for PALA could be explained as 
follows (Figure 35). First, the empty trimer has a very high (nanomolar) affinity for PALA. 
Binding of the inhibitor to one subunit favors partial hinge-closure in the unliganded subunits 
and positioning of the CP-loop that might restrict the entrance of the phosphonate group of 
other PALA molecules. Binding of PALA to a second subunit prompts a further hinge-closure 
and rotation of the Asp-loop in the remaining unoccupied subunit that blocks the active site 
decreasing the affinity for PALA 100-fold. 
 A key question is whether the third active site unoccupied by PALA is still capable of 
efficient catalytic activity. Can the substrates bind to and react well in this vacant site, even if 
PALA cannot? We have not come up (yet) with a good experimental design to answer this 
question. Nevertheless, the finding that huATCase only binds PALA with high affinity in two 
out of the three active sites is surprisingly enough and relevant to understand –at least in 
part– the failure of PALA as an efficient anti-tumoral drug. The lack of therapeutic success is 
complicated, with major contributions from gene amplification (Kempe et al., 1976, Wahl et 
al., 1979), gut toxicity (Grem et al., 1988) and also from the ability of dietary uridine to bypass 
the PALA blockage through salvage pathways. However, at the molecular level, the 
possibility of a resistance mechanism based on the cooperativity between active sites should 
also be considered.  
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Figure 35. huATCase cooperativity model. Schematic representation of the transition of huATCase 
trimer from an open or partially open conformation (light violet) to a closed state (dark violet) with 
active sites saturated with PALA or with substrates. The grey background highlights huATCase states 
for which the structure has been determined. Blue and red arrows indicate respectively higher and 
lower affinity for the ligand. 
 
 Positive cooperativity, on the other hand, is manifested in the sigmoidicity of the 
kinetic curves (Figure 16). Since CP binds first and with equal affinity to the three active sites 
(Figures 19B), cooperativity must arise upon binding of Asp (England et al., 1994). We 
propose that binding of Asp to one subunit facilitates partial hinge-closure of the other CP-
bound subunits (Figure 35). The positioning of the CP-loop and the approximation of the 
Asp-binding elements in the C-domain increase the affinity for Asp. Binding of Asp to a 
second subunit would predispose to the blockage of the third active site by further hinge-
closure and rotation of the Asp-loop. This model implies that at intracellular concentrations of 
Asp (1– 4 mM) (Hansen and Emborg, 1994), only two subunits within huATCase trimer 
would be catalytically competent at a time. Nevertheless, it must be possible to force the 
binding of Asp to the three active sites, in the same manner as huATCase is crystallized with 
three molecules of PALA under high concentrations of the inhibitor.  
 
5. The inhibition by Asp 
 Partial inhibition of the activity at high concentrations of the substrate to be 
carbamylated is a well-documented but poorly understood phenomenon in 
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transcarbamoylases (reviewed in (Shi et al., 2015)). As it has been shown previously for 
other ATCases, we observed that huATCase activity decreases at high Asp concentration 
(Figures 15B). It has been proposed that Asp could bind in a non-productive manner to the 
active site of ATCase, competing with CP, or to a second site in the enzyme (LiCata and 
Allewell, 1997, Pastra-Landis et al., 1978). During this study, we failed to detect the direct 
binding of Asp in absence of CP (Figure 14) and, as far as we know, other titration studies of 
the prokaryotic ATCase with Asp, succinate or malonate did not suggest stoichiometries 
greater than the number of active sites (Allewell and Licata, 1995). Furthermore, the crystal 
structures of prokaryotic ATCases obtained under high concentrations of ligands have not 
shown the aberrant positioning of Asp or of other analogues within the active site. Thus, at 
present, there is no direct evidence of the aberrant binding of Asp in the active site, although 
the possibility cannot be ruled out.  
 According to our model (Figure 35), huATCase activity has an upper limit of two 
active sites per trimer, that would correspond to the highest rate in the Asp saturation curves, 
at 5–7 mM of Asp (Figure 16B). However, we find plausible that the saturation of the three 
active sites with CP and Asp results in a conformation of the trimer similar to the PALA state, 
where increased intersubunit contacts could slow down conformational movements and 
reduce the catalytic turnover. Thus, substrate inhibition would be part of the allosteric and 
cooperative repertoire of ATCase. This idea was first introduced by N. Allewell based on 
analysis of kinetic data with different possible models (LiCata and Allewell, 1997), and finds 
now support in the current results with the human enzyme. 
 
6. Which are the T- and R-states of huATCase? 
 To exhibit cooperativity, the enzyme must be in a conformational equilibrium between 
lower and higher affinity and/or activity states and to transit from one to another upon 
substrate binding (Monod et al., 1965). In the characterization of E. coli ATCase holoenzyme, 
the T-state was assigned to the conformation of the complex free of ligands (Kantrowitz and 
Lipscomb, 1988), whereas the structure of the holoenzyme complexed with PALA was 
assumed to represent the R-state (Kantrowitz and Lipscomb, 1988) (Figure 5). This was 
supported by the fact that substoichiometric amounts of PALA led to a complete 
conformational transition of the holoenzyme and to the activation of all the subunits in the 
complex (Macol 2001) (Kantrowitz, 2012). Lipscomb and colleagues beautifully described 
this transition between inactive and actives states of the holoenzyme, that involves a rotation 
and large separation between the catalytic trimers, with concomitant closure of the subunits 
over the molecules of PALA. However, when Schachman and colleagues solved the 
structure of the isolated ecATC-C3 free and bound to PALA, realized of the similarity with the 
conformations observed in the holoenzyme, they challenged this mechanism of activation. 
They proposed that the activity of ecATCase is not dependent on the open or closed 
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conformations of the subunits, but on the fact that the movements required to catalyze the 
reactions are constraint in the structure of the holoenzyme free of ligands, whereas the 
separation of the catalytic timers upon PALA binding releases the movement of the loops. 
They also question that the structure of the PALA-liganded holoenzyme represented the R-
state since it represents a blocked conformation of the subunits that impedes the free 
exchange of substrates and products in an out the active site.  
 Based on our data, we support the view of Schachman that the structure with three 
PALA molecules bound portrays a closed inhibited trimer unsuitable for interchanging 
substrates and products in and out the active site. As an analog of the true bisubstrate 
complex, the PALA-bound structure defines one of the necessary intermediates that must be 
accessible for the activated subunits to proceed along the catalytic cycle. It is probably that 
PALA freezes a conformation that would otherwise only occur transiently, when the enzyme 
stabilizes the transition state. Thus, in our view, the PALA-structure does not represent the 
active state of the protein. It is only one of the many conformations that huATCase needs to 
go through in order to catalyze the reaction. On the other hand, we also argue that the 
structure of the enzyme free of ligands is not a good representation of the T-state neither, 
since this conformation is only posed to bind CP and shows no affinity for Asp. 
 Since we disagree with the association of the free and PALA-bound structures with 
the T- and R-states, we asked if any of the conformations proposed in our model (Figure 35) 
could account for the equilibrium between low and high affinity/activity conformations 
required for cooperativity. As it has been shown previously, cooperativity only arises upon 
binding of Asp (England et al., 1994) and implies the equilibrium of different states with lower 
or higher affinity for this substrate. The enzyme is only primed to bind Asp if CP loads first in 
the active site. Thus, we propose that the structure of huATCase in complex with CP would 
be a good representation of the enzyme in the T-state. Then, we propose that the trimer 
loaded with CP plus one Asp bound to one of the subunits would represent better the R-
state, since the two subunits that do not have Asp would exhibit increased affinity for this 
substrate. Thus, cooperativity in huATCase would be restricted to the conformational 
equilibrium between huATCase-CP and bound to one Asp molecule (Figure 35). A structure 
partially saturated with PALA or with CP and Asp (or a inert mimic) would be excellent to 
validate the model. Unfortunately, neither this work or the structural characterization of 
bacterial ATCases have shown a catalytic trimer partially saturated with ligands.  
 This could explains why we failed to detect activation by adding small concentrations 
of PALA or succinate (Figure 17). In E. coli ATCase holoenzyme, the inhibition of one subunit 
by the binding of succinate (or PALA) favors the T>R conversion, and thus, the activation of 
the five other subunits in the complex (Stebbins et al., 1989). In contrast, in huATCase, the 
inactivation of one subunit upon binding of succinate or PALA, would result in the activation 
of only two subunits. Furthermore, according to our model (Figure 35), if one of the two 
 121 
activated subunits binds Asp, the remaining subunit will not be catalytically competent due to 
the induced blockage of the active site. In this manner, the activation would be much lower 
than the ecATCase explaining that we could not detect it by the colorimetric assays. 
 
7. Structural bases of cooperativity  
 The isolated ecATC-C3 or other bacterial ATCases that are only catalytic trimers are 
repeatedly described as being non-cooperative (Gerhart and Holoubek, 1967, Porter et al., 
1969, Stebbins et al., 1989). However, landmark studies by Howard Schachman reported 
that only two ecATC-C3 subunits bound PALA with high affinity, while affinity of the third site 
was much lower (Newell et al., 1989). This discrepancy with the identical binding sites 
observed in the crystal structures was attributed to protein damage during isolation and thus, 
it might have not received enough attention. We do not find reasons to suspect that 
huATCase is damaged since, at least for CP, the protein shows three identical and 
equivalent binding sites (Figure 19B). Thus, it is tempting to reinterpret these data also as a 
negative cooperativity effect in the binding of PALA to ecATCase-C3. Nevertheless, since 
ecATCase-C3 kinetic curves are not sigmoidal (Stebbins et al., 1989), the cooperativity 
effects –if any– are diminished compared to huATCase. Although we were convinced of the 
tight structural similarity in the overall fold and virtually identical active sites between 
huATCase and ecATCase-C3, the different kinetic behaviour presupposes structural 
differences between the subunits, and in the way they interact. In this manner, finding these 
differences called for a second and careful comparison of the two structures.  
 The most distinctive feature of huATCase is the tight interconnection through ion-pair 
networks involving the loops H1-S2 (Figure 29A,B). These loops are located at the top end of 
the trimer, surrounding the 3-fold axis and 30 Å away from the active sites. We proved that 
mutations in this loop compromise the oligomerization of huATCase and decrease the affinity 
and cooperativity for PALA. However, ecATCase lacks the interactions through this loop, and 
thus, the stability of the E. coli trimer must depend on the tighter intersubunit contacts at the 
bottom entrance of the central tunnel (Figure 29C). Then, we asked how the huATCase loop 
H1-S2 can affect the functioning of the active site, located on the opposite face of the trimer, 
and participate in the propagation of conformational changes between subunits. We 
observed that closure of the active site upon PALA binding leads to a 0.6-1 Å movement of 
helix H2 and strand S3 along the threefold axis and away from the active site (Figure 26). 
The movement of these two elements shaping the central tunnel directly affects the position 
of the loop H1-S2 and the connection between subunits. Thus, we propose that changes of 
the loop H1-S2 in the unliganded chains could initiate the sequence of events leading to 
hinge-closure in the absence of ligands. Additionally, the more compact conformation of 
huATCase compared to ecATCase-C3 in the PALA state (Figure 25) also suggests that 
communication of conformational changes could be enhanced by the proximity between 
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subunits. We demonstrate that single-point mutations in this loop compromise the 
oligomerization of huATCase (Figure 30B,C,D). Residue E1954 is fully conserved in all the 
CAD sequences that we have found available and it appears to be central for the 
oligomerization of the trimers. Mutation D1958A also reduces the stability of the huATCase 
trimer but the effect is less pronounced. Interestingly, upon addition of CP or PALA, the 
mutants show similar melting temperatures as wild-type, indicating that binding of the ligands 
favours the oligomerization of the protein (Figure 31A,B). 
 Even when the subunits of ecATCase-C3 and B. subtilis ATCase appear to act 
independently, it has been shown that a single mutation of an arginine in the active site is 
sufficient to confer positive cooperativity for Asp (Stebbins and Kantrowitz, 1992, Stebbins et 
al., 1989). The huATCase structures show that the position and interactions of the equivalent 
residue, R2024, are fully conserved with bacterial ATCases (Figure 24B). Remarkably, 
R2024Q has been identified as the causing mutation of the first and only known partial deficit 
of human CAD (Ng et al., 2015). As expected from the position in the active site (Figure 
24A,B) and from the effect of the mutation in bacterial ATCases, R2024Q strongly reduces 
the activity and decreases the affinity for CP and PALA. Most interestingly, R2024Q mutant 
increases the cooperativity and causes an earlier onset in the inhibition by Asp (Figure 33F). 
This indicates that R2024Q mutation facilitates the transition to a closed trimer, and further 
supports that increased intersubunit contacts may slow down conformational movements and 
enzyme turnover. 
 We propose that R2024 –or the equivalent arginine in bacterial ATCases– is part of a 
conformational switch operated by the binding of ligands to the active site (Figure 36). In the 
"open position", the switch arginine points outside of the empty active site, impeding hinge-
closure of the C-domain by steric hindrance and by blocking the interactions with E1971. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. R2024 conformational switch. Detailed view of R2024 interactions in the active site of 
huATCase free (left) or bound to PALA (right). 
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 Binding of ligands switches the arginine to a "closed position" that allows the 
approach of the C-domain, the correct positioning of R2085 to interact with Asp and the 
stabilization of the Asp-loop over the active site. Mutation of the switch arginine increases 
cooperativity by releasing the interactions that restrain the subunits in a low-affinity state, and 
displacing the equilibrium towards a conformation with higher-affinity for Asp.  
 
8. ATCase domain in the context of the complete CAD  
 This work, and previous works carried out in the group, have resulted in the detailed 
characterization of the DHOase (Grande-García et al., 2014) and ATCase domains of human 
CAD. Despite the acquired knowledge about the nuts and bolts of these two domains, we 
lack information on how they assemble together with GLNase and CPSase into hexameric 
particles (Coleman et al., 1977, Lee et al., 1985). There are no many ways in which the CAD 
polypeptides can arrange into a hexamer preserving the symmetries of the DHOase dimers 
and ATCase trimers (Lee et al., 1985, Evans, 1986, Irvine et al., 1997). We support a model 
(Carrey, 1995) in which three CAD polypeptides associate through their ATCase domains 
forming trimers. Two of these trimers could further dimerize between their respective 
DHOases making hexamers. Thus, the ATCase and DHOase domains would have a central 
role in the formation of CAD "dimer of trimers" (Figure 37). In this study, we provide data 
supporting this model. We proved by SEC-MALS that the recombinant huDHOaseATCase 
construct behaves as a hexamer in solution (Figure 34). The sample shows certain 
polydispersity, which could indicate high flexibility of the construct in solution. This flexibility 
can be expected taking into account the lengthy 91-residue linker connecting DHOase and 
ATCase domains. We further corroborated our model by site-directed mutagenesis. The 
mutant M1601E is a trimer in solution, since the mutation hinders the formation of DHOase 
dimers (Figure 34). In turn, mutant D2009A is a dimer in solution, as the mutation 
destabilizes the ATCase trimer. Thus, our results indicate that the DHOase and ATCase 
domains form the core scaffold of the CAD particles. 
 Based on single-particle electron-microscopy (EM) data obtained by other colleagues 
in the group, we have developed a model for the architecture of the CAD particle (Figure 37). 
By using negative staining techniques, we have obtained 2D-averaged images of preferred 
particle orientations of the DHOase-ATCase construct. We combined this low resolution 
information with the high-resolution structures of the human DHOase and ATCase domains 
to build a hypothetical model of the particle. Similar to the models first proposed by Elizabeth 
Carrey and envisioned by David Evans, we placed the two huATCase trimers at the edges of 
the particle, joined together through the interaction with three huDHOase dimers. 
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Figure 37. Hypothetical model of human CAD based in EM and crystallization techniques. 
DHOase and ATCase crystal structures are built together based in the MALS and mutagenesis data. 
CPSase structure shown corresponds to the CPSase I structure solved in the group of Vicente Rubio. 
 
 This arrangement resembles the disposition of the ATCase trimers in ecATCase 
holoenzyme or in the A. aeolicus ATCase complex with DHOase, although the human 
particle is compact and more elongated, expanding approximately 190 Å. We think that these 
two domains assemble to form the structural core of the particle and that the GLNase and 
CPSase domains are ensemble in a second layer around this central element. Future EM 
experiments with full-length CAD should finally reveal the architecture of the protein at high 
resolution. At the moment we have been unable to isolate the GLNase and CPSase domains 
for structural characterization, but we were able to produce full-length CAD protein from other 
organisms (hamster and fungi) and the EM characterization is underway. For the time being, 
we can only build and work on plausible models. Doing so, we were very intrigued by the 
interesting  crystal structure of the human CPSase I determined by the group of Vicente 
Rubio (de Cima et al., 2015). This structure showed the formation of CPSase I dimers within 
the crystal with approximately the same length as the DHOase-ATCase particles. Assuming 
that the CPSase domain of CAD could make dimers similar to the mitochondrial counterpart, 
we propose that six GLNase-CPSase domains could wrap the central DHOase-ATCase core 
forming three dimers. This would result in a compact architecture of the particle where the 
orientation of the domains would favor the communication between active sites. The 
huATCase active sites would be facing the DHOases, while the exit for the long tunnel 
traveling across the GLN-CPSase domains would communicate with the central segment of 
the particle. This arrangement of the CAD subunits seems to fit well with very preliminary 
negative staining EM data collected for the CAD-like complex from Chaetomium 
thermophilum (work in progress) but there is still a long run ahead to reach the final atomic 
view (or views) of this amazing protein. 
 125 
 Regarding the enzymology of the complex, we have not measured yet the enzymatic 
properties of the DHOase-ATCase construct. We hypothesize that since the catalytic rate of 
ATCase is directly related to hinge-movement of the C-domain and to the flexibility of the CP- 
and Asp-loops, it is plausible that these movements are conditioned by the association of 
ATCase with other CAD domains, resulting in a decreased activity of the complex. Indeed, 
the ATCase activity of hamster CAD is ~10-fold higher in the isolated trimer than within the 
full-length protein (Qiu and Davidson, 1998, Qiu and Davidson, 2000). 
 Moreover, the potential ATCase activity within CAD is further limited by the supply of 
CP that is synthetized by CPSase at ~50-fold lower rate (Coleman et al., 1977, Qiu and 
Davidson, 2000). This difference in rates between CPSase and ATCase could be 
advantageous in ensuring that the unstable molecules of CP –produced by CPSase– are 
immediately captured and used by the ATCase. 
 This predicted slower-performance of huATCase within the CAD complex, 
conditioned by interaction with other domains, might explain the clinical effects of mutation 
R2024Q. Although this mutation reduces the activity of the isolated domain 1000-fold it does 
not completely abolish CAD function since huATCase in the CAD complex is not required to 
work at full rate. Furthermore, it has been described that there is a channeling of 
endogenous CP between the CPSase and ATCase active sites (Christopherson and Jones, 
1980). This might help to explain how CAD may overcome the detrimental effect of the 
mutation R2024Q on the affinity for this substrate.  
 These thoughts are relevant to understand that inhibiting the active site of ATCase 
domain might not be the most effective strategy to compromise the activity of CAD. Targeting 
the CPSase domain, which catalyzes the limiting step of the overall reaction and is the point 
of allosteric control, could be much more effective for drug design. 
 We also speculate on the possibility that similarly to the E. coli ATCase holoenzyme, 
where the association through regulatory dimers confers cooperativity to the catalytic 
subunits, the association of two huATCase trimers within the CAD complex might enhance 
the cooperativity effects described in this study. It will be very interesting to assay which is 
the cooperativity of ATCase within the DHOaseATCase construct. If the cooperativity turns 
out to be increased, this would have implications for the fine-tuning of CAD activity to small 
variations in the intracellular concentration of Asp. On the other hand, higher cooperativity 
between subunits could also result in larger impediments for PALA binding in CAD particles 
partially saturated with the inhibitor. Further insight into the functioning and inhibition of the 
ATCase domain awaits the detailed characterization of the DHOaseATCase complex and on 
the entire CAD particle. 
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1. We have produced the ATCase domain of human CAD as an independent and 
catalytically active recombinant protein. 
2. The isolated huATCase domain forms trimers in solution for which the dissociation 
constant has been estimated. 
3. We have determined the crystal structures of huATCase in the apo-form, bound to 
CP and in complex with the inhibitor PALA 
4. The crystal structures corroborate the predicted overall similarity with bacterial 
ATCase catalytic trimers. 
5. huATCase is a homotrimer, where the subunits undergo large conformational 
changes upon binding of ligands to the active sites. 
6. Contrary to the isolated bacterial ATCase catalytic trimers, huATCase shows positive 
cooperative for substrate binding and negative cooperativity for PALA binding. 
7. We combined structural analysis and mutagenesis to identify the distinctive structural 
elements responsible for the communication and cooperativity among huATCase 
subunits.  
8. We have produced and characterized the huATCase mutant R2024Q, described to 
cause the first human disease associated with a CAD-deficit. We propose that 
residue R2024 is part of a conformational switch controlling the conformational 
changes of the subunits upon ligand binding. 
9. We produced a bifunctional construct harboring the ATCase and DHOase domains of 
human CAD and proved that they form the hexameric core scaffold of the CAD 
particles.  
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1. Hemos producido, de manera recombinante, el dominio ATCasa de la CAD humana 
(huATCasa), que se comporta como una proteína independiente y es catalíticamente 
activa. 
2. El dominio huATCasa aislado forma trímeros en solución, para el cual hemos 
calculado su constante de disociación.  
3. Hemos determinado las estructuras cristalográficas de huATCasa en la forma apo, 
asociada a CP y en complejo con el inhibidor PALA. 
4. Las estructuras cristalográficas corroboran la similud con los trímeros catalíticos de 
las ATCasas bacterianas. 
5. Las subunidades de huATCasa sufren grandes cambios conformacionales al unirse 
los ligandos al sitio activo. 
6. Al contrario que los trímeros catalíticos de las ATCasas bacterianas, huATCasa 
muestra cooperatividad positiva para la unión de los ligandos y cooperatividad 
negativa para la unión de PALA. 
7. Hemos combinado análisis estructurales y mutagénicos para identificar los 
elementos estructurales específicos responsables de la comunicación y 
cooperatividad entre las subunidades de huATCasa. 
8. Hemos producido y caracterizado el mutante de huATCasa R2024Q, causante de la 
primera y única enfermedad humana descrita asociada a CAD. Proponemos que el 
residuo R2024 es parte de un mecanismo conformacional que controla los cambios 
producidos en las subunidades tras la unión de los ligandos. 
9. Hemos producido la construcción bifuncional que contiene los dominios DHOasa y 
ATCasa de CAD humana y hemos demostrado que estos forman el núcleo de 
hexamerización de las partículas de CAD. 
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